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Apicomplexan infections cause substantial morbidity and mortality, worldwide. New,
improved therapies are needed. Herein, we create a next generation anti-apicomplexan
lead compound, JAG21, a tetrahydroquinolone, with increased sp3-character to improve
parasite selectivity. Relative to other cytochrome b inhibitors, JAG21 has improved
solubility and ADMET properties, without need for pro-drug. JAG21 significantly reduces
Toxoplasma gondii tachyzoites and encysted bradyzoites in vitro, and in primary and
established chronic murine infections. Moreover, JAG21 treatment leads to 100%
survival. Further, JAG21 is efficacious against drug-resistant Plasmodium falciparum
in vitro. Causal prophylaxis and radical cure are achieved after P. berghei sporozoite
infection with oral administration of a single dose (2.5 mg/kg) or 3 days treatment at
reduced dose (0.625 mg/kg/day), eliminating parasitemia, and leading to 100% survival.
Enzymatic, binding, and co-crystallography/pharmacophore studies demonstrate
selectivity for apicomplexan relative to mammalian enzymes. JAG21 has significant
promise as a pre-clinical candidate for prevention, treatment, and cure of toxoplasmosis
and malaria.
Keywords: Toxoplasma gondii, Plasmodium falciparum, cytochrome bc1, tetrahydroquinolone, nanoformulation,
structure-guided design, transcriptomics, RPS131
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INTRODUCTION
Malaria results in the death of ∼0.5 million children a year,
with drug resistance impacting the usefulness of successive
generations of new medicines (www.who.int/malaria/
publications/world-malaria-report-2017/en/). The related
apicomplexan parasite, Toxoplasma gondii, is the most frequent
parasitic infection of humans in the world. It plays a significant
role in food-borne associated death in the USA, destruction
of the human retina (Phan et al., 2008), and death and illness
from recrudescent disease in the immune compromised or
immunologically immature (McLeod et al., 2006; McLeod and
Boyer, 2019). It has been estimated that there are 1.9 million
new cases of this congenital T. gondii infection globally over
a 10 year period, causing 12 million disability adjusted life
years (Torgerson and Mastroiacovo, 2013) from damage to
the fetal brain and eye. Toxoplasmosis is an often neglected,
untreated, or mistreated disease. There are ∼2 billion people
throughout the world who have this parasite in their brain
lifelong, some with known, severe, adverse consequences (Delair
et al., 2011; Wallon et al., 2013; Lykins et al., 2016). There are
possible additional, harmful effects for a substantial number of
chronically infected people as this parasite modulates signature
pathways of neurodegeneration, motor diseases, epilepsy, and
malignancies (Ngô et al., 2017). No medicine eliminates this
chronic, encysted form of the parasite. New and improved
medicines are greatly needed to cure Toxoplasma and Plasmodia
infections (McLeod et al., 2006). These parasites often share the
same molecular targets for medicines due to a relatively close,
apicomplexan, phylogenetic relationship (McPhillie et al., 2016).
Thus, medicine development for each of these parasites can
inform development of medicines that benefit treating the other
(Muench et al., 2007; Fomovska et al., 2012a).
One such shared molecular target is the mitochondrial
cytochrome bc1 complex that is important for the survival
of apicomplexan parasites such as Plasmodia and T. gondii.
Cytochrome b is a subunit of the cytochrome bc1 complex,
an inner mitochondrial membrane protein that is part of the
electron transport chain. Activity of this complex is integral to
oxidative phosphorylation and generation of ATP (Vercesi et al.,
1998). Cytochrome b activity appears to be necessary for the
replication and persistence of the parasite (McPhillie et al., 2016),
and is the site of action of atovaquone (McPhillie et al., 2016).
Cytochrome b is the target for quinolone-based compounds, but,
significant problems with solubility, and toxicity have been noted
with earlier cytochrome b inhibitors. In an attempt to design
novel quinolone-like inhibitors with improved solubility, and
lower toxicity, compared to known compounds in the literature,
we synthesized a series of tetrahydroquinolinones (THQs). Our
preliminary efforts were described in McPhillie et al. (2016). We
reasoned that the increased “sp3” character of the THQs (i.e.,
moving from rod-like to sphere-like 3D space) could provide
the required improvement in solubility that would allow for
optimal pharmacokinetic properties.Molecules with an increased
percentage of “sp3 character” tend to be more three-dimensional,
than their planar (“sp2-rich”) counterparts. The terms “sp2” and
“sp3” refer to the shape of their hybridized atomic orbitals, which
have trigonal planar and tetrahedral geometries, respectively.
Flat aromatic rings (“sp2-rich”) are ubiquitous in drug discovery
campaigns, but molecules with more “sp3 character” are often
more specific for their protein target and can have better
physicochemical properties. Further, we reasoned that the larger
binding pocket in the parasite enzymes (McPhillie et al., 2016),
compared to their mammalian counterparts, would provide
room for bulkier substituents to minimize effect on the human
enzyme. Within this new series of compounds, we aimed to
identify amature lead compoundwith both anti-Plasmodium and
anti-T. gondii activity.
Our work developed as follows: We recently found markedly
increased expression of cytochrome b in the currently untreatable
T. gondii bradyzoite life-cycle stage (McPhillie et al., 2016).
Thus, we set out to develop a compound that would inhibit
tachyzoites, bradyzoites, and three life cycle stages of even
drug-resistant Plasmodia. We sought to do this without a
need for a pro-drug as has been needed in other attempts to
target apicomplexan cytochrome b (Frueh et al., 2017). Our
aim was to improve upon the physicochemical properties of
napthoquinones and endochin-like quinolones (ELQs) targeting
cytochrome b, including poor aqueous solubility and toxicity
(Khan et al., 1998; Doggett et al., 2012; Capper et al., 2015; Miley
et al., 2015; McPhillie et al., 2016). The intent was further to
provide potential solutions for limitations of other compounds
active against apicomplexan parasites (Waxman and Herbert,
1969; Caumes et al., 1995). Our concurrent crystallographic
studies also enable better understanding of the interactions
between ligand and the binding pocket of the Qi site (McPhillie
et al., 2016).
Herein, we have identified a preclinical lead candidate
based on potent and selective inhibition of Plasmodium
falciparum, Plasmodium berghei, and T. gondii cytochrome bc1
for the treatment of malaria and toxoplasmosis. The candidate
compound demonstrates high efficacy in relevant in vitro and
in vivo models of the diseases, and has considerable potential
for broad-spectrum use (i.e., against T. gondii tachyzoites
and encysted bradyzoites, and drug resistant Plasmodia). The
data which follow present the creation and characterization of
this novel, broad-spectrum, anti-apicomplexan lead compound
which has promise for definitive treatment of these infections.
MATERIALS AND METHODS
Syntheses of Compounds
Synthesis of Tetrahydroquinolones (THQs)
Compounds
The THQ compounds were synthesized at the University of
Leeds as described below. Ten millimolars stock solutions were
made with 100% Dimethyl Sulfoxide (DMSO) [Sigma Aldrich]
and working concentrations were made with IMDM-C (1x, [+]
glutamine, [+] 25mM HEPES, [–] Phenol red, 10% FBS)[Gibco,
Denmark]). Compounds are shown in Figure 1A. Compound
name with “0” or no “0” between letters and number, e.g., JAG21
or JAG021, refer to the same compound. This is throughout
the manuscript. Final compounds had >95% purity determined
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by high performance liquid chromatography (HPLC), high
resolution mass spectrometry, and NMR spectrometry. Liquid
chromatography-mass spectrometry (LC-MS) and NMR
spectrometry were used to determine the integrity and purity
of all intermediates. THQ compounds were synthesized as
described in Schemes 1, 2, which describe compounds MJM170
and JAG21 as exemplars. Building blocks 1, 8, 9, and 14 were
varied to create the complete series (Figure 1A).
Synthesis of
2-Methyl-5,6,7,8-Tetrahydroquinolin-4-one (2)
Platinum oxide (0.100 g, 10mol %) was added to a solution of
4-hydroxy-2-methylquinoline (1, 1.00 g, 6.28 mmol, 1.00 eq) in
glacial acetic acid (10.0mL). The heterogeneous mixture was
catalytically hydrogenated under a balloon of hydrogen. After
22 h, TLC (10% MeOH–DCM) confirmed complete reaction.
The mixture was filtered through celite under vacuum, washing
thoroughly with EtOAc (50mL). The filtrate was concentrated
and the resulting residue purified by column chromatography
(10% MeOH–DCM) to give the desired product as a pale yellow
oil (0.917 g, 5.65 mmol, 89%); Rf 0.14 (10% MeOH–DCM); δH
(300 MHz, CDCl3) 1.74–1.76 (4H, m, CH2), 2.29 (3H, s, Me),
2.49–2.52 (2H, m, CH2), 2.67–2.70 (2H, m, CH2), 6.16 (1H, s,
Ar-H); δC (125MHz, CDCl3) 19.0 (Me), 21.8 (CH2), 22.1 (CH2),
27.1 (CH2), 112.5 (CH), 122.4 (Cq), 146.4 (Cq), 147.0 (Cq),
178.3 (Cq); Spectroscopic data consistent with literature values
(Bradbury et al., 1993).
Synthesis of
2-Methyl-3-iodo-5,6,7,8-Tetrahydroquinolin-4-One (3)
nButylamine (6.20mL, 62.8 mmol, 10.0 eq) was added to
a suspension of 2-methyl-5,6,7,8-tetrahydroquinolin-4-one (2,
1.02 g, 6.28 mmol, 1.00 eq) in DMF (10.0mL). To this
heterogeneous mixture was added I2 (1.60 g, 6.28 mmol, 1.00 eq)
in a saturated solution of KI (6.00mL). After 20 h stirring at R.T.,
a precipitate formed in the orange solution, excess iodine was
quenched with 0.1M sodium thiosulfate solution (10.0mL). The
precipitate was filtered by vacuumfiltration, washedwith distilled
H2Oand dried (Na2SO4) to give the desired product as a colorless
solid (1.76 g, 6.09mmol, quantative yield); δH (300MHz,DMSO-
d6) 1.61–1.70 (4H, m, CH2), 2.29 (2H, t, J 6.0, CH2), 2.43 (2H, s,
CH2), CH3 under DMSO peak.
Synthesis of 2-Methyl-3-Iodo-4-Ethoxy-5,6,7,8-
Tetrahydroquinoline (4)
Potassium carbonate (1.53 g, 11.1 mmol, 2.00 eq) was added
to a heterogeneous mixture of 2-methyl-3-iodo-5,6,7,8-
tetrahydroquinolin-4-one (3, 1.60 g, 5.56 mmol, 1.00 eq) in DMF
(15.0mL), and the reaction heated to 50◦C for 30min. The R.B.
flask was removed from the heating mantle and ethyl iodide
(0.67mL, 8.33 mmol, 1.50 eq) was added dropwise. The reaction
was then heated at 50◦C for 18 h. The reaction was cooled to
R.T., quenched with water (40mL). The resulting emulsion
formed which was extracted with EtOAc (50mL). EtOAc layer
were washed with water (3 × 30mL), brine (3 × 30mL), dried
(Na2SO4) and concentrated to give a pale yellow oil (1.09 g, 3.44
mmol, 61%); Rf 0.88 (1:1 Pet–EtOAc); HPLC (RT = 1.67min);
LCMS (Method A), (RT= 1.6min,m/z (ES) FoundMH+ 318.0);
δH (500 MHz, CDCl3) 1.49 (3H, t, J 7.0, ethoxy CH3), 1.73–1.78
(2H, m, CH2) 1.84–1.88 (2H, m, CH2), 2.78–2.69 (5H, m, CH2
& CH3), 2.84 (2H, t, J 6.5, CH2), 3.97 (2H, q, J 7.0, OCH2); δC
(125 MHz, CDCl3) 15.6 (CH3), 22.3 (CH2), 22.8 (CH2), 23.6
(CH2), 29.3 (CH3), 32.0 (CH2), 68.4 (OCH2), 90.9 (Cq), 124.5
(Cq), 158.3 (Cq), 158.9 (Cq), 163.9 (Cq).
Synthesis of 2-Methyl-3-(4-Phenoxyphenyl)-4-
Ethoxy-5,6,7,8-Tetrahydroquinoline (6)
2-Methyl-3-iodo-4-ethoxy-5,6,7,8-tetrahydroquinoline (4,
0.266 g, 0.839 mmol, 1.00 eq), Pd(PPh3)4 (0.048 g, 0.0419 mmol,
5 mol%) and 4-phenoxyphenylboronic acid (5, 0.270 g, 1.26
mmol, 1.50 eq) were charged to a R.B. flask under N2(g).
Degassed DMF (10.0mL) was added to the flask followed by 2M
K2CO3 (1.60mL). The flask was heated to 85◦C under N2(g).
After 15min, TLC (4:1 Pet–EtOAc) confirmed reaction was
complete. The reaction was cooled and diluted with EtOAc
(15mL), filtered through celite and partitioned between EtOAc
(10mL) and H2O (25mL). Combined organics were washed
with H2O (3 × 30mL), then brine (3 × 30mL), dried (Na2SO4)
and concentrated to give a red oil which was purified by column
chromatography (3:1 Pet–EtOAc), to give the desired product
as a pale yellow oil (0.235 g, 0.655 mmol, 78%); Rf 0.31 (3:1
Pet–EtOAc); HPLC (RT = 3.08min); δH (300 MHz, CDCl3)
1.04 (3H, t, J 7.0, ethoxy CH3), 1.76–1.93 (4H, m, 2xCH2), 2.32
(3H, s, CH3) 2.72 (2H, t, J 6.0, CH2), 2.91 (2H, t, J 6.5, CH2),
3.50 (2H, q, J 7.0, OCH2), 7.05–7.16 (5H, m, Ar-H), 7.20–7.29
(2H, m, Ar-H), 7.31–7.43 (2H, m, Ar-H); δC (125 MHz, CDCl3)
15.7 (CH3), 22.5 (CH2), 23.0 (CH3), 23.3 (CH2), 23.4 (CH2),
32.7 (CH2), 68.2 (OCH2), 118.6 (CH), 118.9 (CH), 123.4 (CH),
126.8 (Cq), 129.8 (CH), 131.5 (CH), 154.9 (Cq), 156.5 (Cq), 157.1
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SCHEME 1 | Synthesis of hit compound 7, also known as MJM170 (McPhillie et al., 2016). Synthetic scheme inspired by the route to endochin-like quinolones (ELQs)
reported by Doggett et al. (2012).
(Cq), 157.3 (Cq);m/z (ES) (Found: MH+, 360.1973. C24H26NO2
requiresMH, 360.1964).
Synthesis of 2-Methyl-3-(4-Phenoxyphenyl)-4-
Ethoxy-5,6,7,8-Tetrahydroquinoline (7,
MJM170)
Aqueous hydrobromic acid (>48%) (1.00mL) was added to
a solution of 2-methyl-3-(4-phenoxyphenyl)-4-ethoxy-5,6,7,8-
tetrahydroquinoline (6, 0.226 g, 0.630 mmol, 1.00 eq) in glacial
acetic acid (2mL). The reaction was stirred at 90◦C for 5 days,
monitoring by LMCS. The reaction was cooled to R.T. and the pH
adjusted to pH 5 with 2M NaOH. The precipitate was collected
by vacuum filtration and recrystallized from MeOH:H2O to give
the desired product as an off-white solid (0.155 g, 0.467 mmol,
74%); HPLC (RT = 2.56min); δH (500 MHz, DMSO-d6) 1.66–
1.72 (4H, m, 2xCH2), 2.08 (3H, s, CH3) 2.31 (2H, t, J 6.0, CH2),
2.56 (2H, t, J 6.0, CH2), 6.99 (2H, d, J 8.5, Ar-H), 7.06 (2H, d, J
7.5, Ar-H), 7.14–7.18 (3H, m, Ar-H), 7.40–7.43 (2H, m, Ar-H),
11.0 (1H, s, NH); δC (125 MHz, DMSO-d6) 17.7 (CH3), 21.5
(CH2), 21.8 (CH2), 21.9 (CH2), 26.2 (CH2), 117.8 (CH), 118.6
(CH), 121.2 (Cq), 123.3 (CH), 123.7 (Cq), 130.0 (CH), 131.4 (Cq),
132.3 (CH), 142.3 (Cq), 143.2 (Cq), 155.0 (Cq), 156.8 (Cq), 175.4
(Cq); m/z (ES) (Found: MH+, 332.1654. C22H22NO2 requires
MH, 332.1645).
Synthesis of
1-(4-Bromophenyl)-4-(Trifluoromethoxy)Benzene (10)
Copper (II) acetate (0.435 g, 2.39 mmol, 1.00 eq) was added to
a suspension of 4-bromophenol (8, 0.414 g, 2.39 mmol, 1.00 eq),
4-trifluoromethoxybenzeneboronic acid (9, 0.983 g, 4.79 mmol,
2.00 eq) and 4 Å molecular sieves (0.566 g) in DCM (12mL)
at R.T. A solution of triethylamine (1.7mL, 11.9 mmol, 5.00
eq) and pyridine (1mL, 11.9 mmol, 5.00 eq) was added and
the reaction was stirred for 16 h, open to the atmosphere. After
18 h, the reaction was quenched with 0.5M HCl (20mL) and the
organic layer washed with water (20mL), brine (20mL), dried
(Na2SO4), and concentrated to give a red oil which was purified
by column chromatography (hexane) to give the desired product
as a colorless oil (0.582 g, 1.75 mmol, 73%); Rf 0.58 (hexane).
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SCHEME 2 | Synthetic route to analogs of 7 (MJM170) via route A or route B. Route A is the original route to analogs but is linear and involves a tricky Suzuki step to
intermediate 12 from intermediates 4 and 10. Route B allows quicker access to analogs since intermediate 15 can be made in larger quantities and derivatives can be
synthesized via the Chan-Lam reaction to give final intermediate 12 by varying the boronic acid 16.
Synthesis of 2-Methyl-3-(4-Hydroxyphenyl)-4-
Ethoxy-5,6,7,8-Tetrahydroquinolin-4-One (15)
2-Methyl-3-iodo-4-ethoxy-5,6,7,8-tetrahydroquinoline (4,
0.400 g, 1.26 mmol, 1.00 eq), Pd(PPh3)4 (0.073 g, 0.06 mmol,
5 mol%) and 4-hydroxylphenylboronic acid (14, 0.260 g, 1.89
mmol, 1.50 eq) were charged to a R.B. flask under N2(g).
Degassed DMF (10.0mL) was added to the flask followed by 2M
K2CO3 (3.00mL). The flask was heated to 85◦C under N2(g).
After 3 h, TLC (EtOAc) confirmed reaction was complete. The
reaction was cooled to 50◦C, diluted with EtOAc (15mL) and
activated charcoal was added. After stirring for 30min, the
mixture was filtered through celite and partitioned between
EtOAc (10mL) and H2O (25mL). Combined organics were
washed with H2O (3 × 30mL), then brine (3 x 30mL), dried
(Na2SO4) and concentrated to give a brown solid which was
triturated with diethyl ether to give the desired product as a
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FIGURE 1 | Characteristics and effects of compounds on inhibition of Toxoplasma gondii replication and enzyme activity, and Structure Activity Relationship analysis.
(A) Cytochrome b/c inhibitor code, Chem Draw structure, solubility in PBS 7.4, toxicity against HFF, predicted half-life, and inhibitory effect of compounds on RH strain
tachyzoites and EGS strain bradyzoites in vitro and saffarine O assay enzyme activity. PBS Sol/Toxicity pH7.4 refers to solubility of the compound in Phosphate
Bufferred Saline (PBS) at pH 7.4. Toxicity refers to the highest concentration tested that does not show toxicity to Human Foreskin Fibroblast (HFF) in tissue culture in
WST assay; T1/2 (H) refers to the predicted half-life in human liver microsomes; T1/2 (M) refers to the predicted half-life in mouse liver microsomes. Tachy/Brady IC50
(Continued)
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FIGURE 1 | was determined in studies in which cultures of parasites in HFF were treated with varying concentrations of the compound and there was 50% inhibition
of the replication (number) of parasites. Parasites were RH-YFP expressing tachyzoites (Tachy) and EGS (Brady) strains. Studies of effects of inhibitors on HFF or on T.
gondii tachyzoites were performed with triplicate wells in at least 2 biological replicate experiments. Studies of effects on bradyzoites were performed at least twice in
at least 2 biological replicate experiments. Compounds with much less inhibition of mammalian than T. gondii cytochrome bc, relative to JAG21 effect on parasite
enzyme, in the saffarine enzyme assay (indicated by **) provide potential to further develop compounds, if unanticipated toxicity occurs from JAG21. (B) Structure
Activity Relationship analysis (SAR). The effects of changing R1 as 7-Et, 7-Me, 6-CF3, or 6-Me on activity against T. gondii RH strain tachyzoites, solubility, and stability
were compared in the SAR. Color Key in (B) Activity: Green <50 nM, Red > 1µM; Solubility in 100mM Phosphate Buffer (pH 7.4): Amber>10µM, Red <10µM;
Metabolic Stability: Green >120min, Amber 60–120min, red < 60min. SAR panel displays only representative structures and trends within the JAG compound
series. JAG21 (blue font) is highly active, has the longest predicted half-life for humans of initial compounds tested (green), combined with improved solubility, no
hERG liability, and predicted capacity to cross the blood brain barrier (BBB). Definitions of ADMET terminology are in the Materials and Methods. In summary, in the
SAR overall, nitrogen atoms were not tolerated in aryl ring marked by green c, and the 4-position was optimal for phenol substituent. Compound name with “0” or no
“0” between letters and number, e.g., JAG21 or JAG021, refer to the same compound. This is throughout the manuscript.
pale red crystalline solid (0.220 g, 0.777 mmol, 60%); Rf 0.22
(EtOAc); m.p. 225–226◦C (EtOAc); δH (500 MHz, MeOD-d4)
7.07 (d, J = 8.6Hz, 2H, H-3 & 5), 6.86 (d, J = 8.6Hz, 2H, H-2 &
6), 3.51 (q, J = 7.0Hz, 2H, CH3CH2O), 2.83 (t, J = 6.3Hz, 2H,
H-8’), 2.72 (t, J = 6.1Hz, 2H, H-5’), 2.23 (s, 3H, Me), 1.95–1.72
(m, 4H, H-6’ & 7’), 1.00 (t, J = 7.0Hz, 3H, CH3CH2O); δC (125
MHz, MeOD-d4) 164.0 (Cq), 158.1 (C-1), 157.4 (Cq), 156.1 (Cq),
132.2 (C-3 & 5), 129.1 (Cq), 127.9 (Cq), 124.9 (Cq), 116.2 (CH),
69.1 (OCH2), 32.7 (CH2), 23.9 (CH2), 23.4 (CH3), 22.9 (CH2),
22.3 (CH2), 15.7 (CH3); m/z (ES) (Found MH+, 284.1664,
C18H21NO2 requiresMH, 284.1651).
Synthesis of 2-Methyl-3-(4-Hydroxyphenyl)-4-
Ethoxy-5,6,7,8-Tetrahydroquinolin-4-One
(12)
1-(4-bromophenyl)-4-(trifluoromethoxy)benzene (10, 0.100 g,
0.30mmol, 1.00 eq), bis(pinacolato) diboron (1.10 eq), potassium
acetate (3.00 eq) and Pd(dppf)Cl2 (0.03 eq) were added to a
oven-dried flask under inert (N2) atmosphere. Anhydrous DMF
(6mL) was added and the reaction heated to 80◦C under N2 (g).
After 22 h, the reaction was cooled to R.T., fresh Pd(dppf)Cl2
(0.03 eq) added, followed by 2-methyl-3-iodo-4-ethoxy-5,6,7,8-
tetrahydroquinoline (4, 0.400 g, 1.26 mmol, 2.00 eq) and 2M
Na2CO3 (2.9mL). The reaction was heated to 80◦C for 20 h,
cooled, diluted with EtOAc (20mL), filtered through celite
and partitioned between EtOAc (20mL) and H2O (20mL).
Combined organics were washed with brine (3 × 20mL), dried
(Na2SO4) and concentrated to give a brown solid which was
purified by column chromatography (3:1 Pet–EtOAc) to give
the desired product as a colorless oil (30mg, 0.07 mmol, 23%);
HPLC (RT = 2.41min); δH (500 MHz, acetone) 7.28 (d, J =
8.7Hz, 2H, H-2
′
& 6
′
), 7.26 (d, J = 9.1Hz, 2H, H-2
′′
& 6
′′
),
7.09 (d, J = 9.1Hz, 2H, H-3
′′
& 5
′′
), 7.07 (d, J = 8.7, 2H, H-3
′
& 5
′
), 3.52 (q, J = 7.0Hz, 2H, CH3CH2O), 2.85 (t, J = 6.5Hz,
2H, H-8), 2.78 (t, J = 6.2Hz, 2H, H-5), 2.26 (s, 3H, Me), 1.89–
1.81(m, 2H, H-7), 1.81–1.72 (m, 2H, H-6), 0.93 (t, J = 7.0Hz,
3H, C H3CH2O); δC (125 MHz, acetone) δ 161.9 (Cq), 157.1
(Cq), 156.5 (Cq), 156.0 (Cq), 154.5 (Cq), 145.3 (Cq), 132.5 (Cq),
132.0 (CH), 126.7 (Cq), 123.0 (CH), 119.8 (CH), 119.0 (CH),
68.0 (OCH2), 32.5 (CH2), 23.0 (CH2), 22.9 (CH3), 22.7 (CH2),
22.5 (CH2), 15.05 (CH3); m/z (ES) (Found: MH+, 444.1792.
C25H24F3NO3 requiresMH, 444.1781).
Synthesis of
2-Methyl-3-(4-(4-(Trifluoromethoxy)Phenoxy)Phenyl)-
5,6,7,8-Tetrahydroquinolin-4-One (13,
JAG21)
Aqueous hydrobromic acid (>48%) (1.00mL) was added to
a solution of 2-methyl-3-(4-phenoxyphenyl)-4-ethoxy-5,6,7,8-
tetrahydroquinoline (12, 30.0mg, 0.07 mmol, 1.00 eq) in glacial
acetic acid (2mL). The reaction was stirred at 90◦C for 3 days,
monitoring by LMCS. The reaction was cooled to R.T. and the pH
adjusted to pH 5with 2MNaOH. The precipitate was collected by
vacuum filtration and recrystallized fromMeOH:H2O to give the
desired product as a colorless solid (25.0mg, 0.06 mmol, 68%);
m.p.>250◦C;HPLC (RT= 2.78min); δH (500MHz,DMSO-d6)
11.07 (s, 1H, NH), 7.40 (d, J= 8.5Hz, 2H, H-2
′
& 6
′
), 7.19 (d, J =
8.6Hz, 2H, H-3
′′
& 5
′′
), 7.13 (d, J = 9.0Hz, 2H, H-3
′
& 5
′
), 7.02
(d, J = 8.5Hz, 2H, H-2
′′
& 6
′′
), 2.54 (t, J = 6.0Hz, 2H, H-8), 2.28
(t, J= 5.9Hz, 2H, H-5), 2.07 (s, 3H, Me), 1.71 (m, 2H, H-7), 1.65
(m, 2H, H-6); δC (125 MHz, DMSO-d6) 175.7 (Cq), 155.9 (Cq),
154.5 (Cq), 143.5 (Cq), 143.2 (Cq), 142.2 (Cq), 132.5 (CH), 132.2
(Cq), 123.6 (Cq), 123.0 (CH), 121.3 (Cq), 119.6 (CH), 118.2 (CH),
26.2 (CH2), 21.9 (CH2) 21.8 (CH2), 21.5 (CH2), 17.7 (CH3);
m/z (ES) (Found: MH+, 416.1492. C23H20F3NO3 requires
MH, 416.1473).
Toxoplasma gondii
Parasite Strains (Isolates)
RH-YFP tachyzoites (Gubbels et al., 2003; Fomovska et al., 2012a;
McPhillie et al., 2016), EGS strain (Vidigal et al., 2002; Paredes-
Santos et al., 2013, 2018; McPhillie et al., 2016), Pru-luciferase,
Me49, and RPS131 on the RH strain background (Hutson et al.,
2010) were prepared and passaged in human foreskin fibroblasts
[HFF] as described.
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T. gondii in vitro
In vitro Challenge Assay for T. gondii
RH strain YFP Tachyzoites. Protocol was adapted from
Fomovska et al. (2012a,b) for HFF. HFF were cultured on a
flat, clear-bottomed, black 96-well plate to 90–100% confluence.
IMDM (1x, [+] glutamine, [+] 25mM HEPES, [+] Phenol red,
10% FBS [Gibco, Denmark]) was removed and replaced with
IMDM-C(1x, [+] glutamine, [+] 25mMHEPES, [–] Phenol red,
10% FBS)[Gibco, Denmark]). RH-YFP, lysed from host cells by
passing twice through a 27-gauge needle, were counted, then
diluted to 32,000/mL in IMDM-C. HFF were infected with 3200
RH-YFP, then returned to 37◦C, CO2 (5%) incubator for 1–2 h
for infection. Various concentrations of the compounds in 20 µL
IMDM-C were added to each well. There were triplicates for each
condition. Controls were pyrimethamine/sulfadiazine (standard
treatment), 0.1% DMSO only, HFF only, and untreated cultures
of HFF infected with 2-fold dilutions of YFP expressing parasites
(called “YFP gradient” to establish amount of color from known
numbers of YFP expressing parasites). Cells were incubated at
37◦C for 72 h. Plates were read using a fluorimeter (Synergy
H4 Hybrid Reader, BioTek) to ascertain amount of relative
fluorescence units (RFU) YFP, to measure parasite burden after
treatment. Data were collected using Gen5 software with IC50
calculated by graphical analysis in Excel.
An initial screening assay of 10µM, 1µM, 100 nM, and
10 nM of the compounds was performed. Compounds were not
considered effective or pursued for further analysis if there was
no inhibition of tachyzoites at 1µM. If compounds were effective
at 1µM, another experiment was performed to assess effect at
1µM, 500, 250, 125, 62.5, and 31.25 nM.
Cytotoxicity Assays in Parallel With RH Strain
T. gondii in vitro Studies
Toxicity assays used WST-1 cell proliferation reagent (Roche)
as in Fomovska et al. (2012a). HFF were grown on a flat,
clear-bottomed, black 96-well plate. Confluent HFF were treated
with inhibitory compounds at concentrations of 10 and 50µM.
Compounds were diluted in IMDM-C, and 20 µL were added
to each designated well, with triplicates for each condition. A
gradient with 2-folddecreasing concentrations of DMSO from 10
to 0% in colorless, translucent IMDM-C was used as a control.
The plate was incubated for 72 h at 37◦C. Ten microlitre WST-1
reagent (Roche) were added to each well. Cells were incubated for
30–60min. Absorbance was read using a fluorimeter at 420 nm.
A higher degree of color change (and absorbance) indicated
mitochondrial activity and cell viability.
In vitro Challenge Assay for EGS Strain Bradyzoites
HFF cells were grown in IMDM on removable, sterile glass
cover slips in the bottom of a clear, flat-bottomed 24-well plate.
Cultures were infected with 3 × 104 EGS strain parasites per
well, in 0.5mL media. The plate was returned to incubator at
37◦C overnight. The following day, the media was removed.
Colorless IMDM and compounds were added to make various
concentrations of the drug. Total volume was 0.5mL. Two wells
had media only, as a control. Plates were returned to the 37◦C
incubator for 72 h, checked once each 24 h. If tachyzoites were
visible in the control before 72 h, cells were fixed and stained.
Cells were fixed using 4% paraformaldehyde and stained
with Fluorescein-labeled Dolichos Biflorus Agglutinin, DAPI,
and antibody to BAG1. Disks were removed, mounted on
glass slides, and visualized using microscopy (Nikon Tl7).
Slides were scanned using a CRi Panoramic Scan Whole Slide
Scanner and viewed using Panoramic Viewer Software. Effects
of compounds were quantitated by counting cysts in controls
and treated cultures. Dolichos staining delimited structures and
single organisms that remained were counted in a representative
field of view. This was then multiplied by a factor determined by
the total area of the cover slip in order to estimate the number
of cysts and organisms in each condition. When the following
forms were observed: “true cysts” with a dolichos-staining wall,
“pseudocysts” or tight clusters of parasites, and small organisms,
if there were fewer than four parasites visible in a cluster,
organisms were counted individually (as “small organisms”). The
entire scanned coverslip with all fields was also reviewed by 3
observers to confirm consistency.
Synergy Studies With RH Strain YFP Tachyzoites
Atovaquone and pyrimethamine were used to test whether they
are synergistic with JAG21. Serial dilutions of the combination
of JAG21 and either atovaquone or pyrimethamine were used
in an in vitro challenge assay as described above. The EC50
of each compound and the combination of two compounds
were determined. The effect of the combination of drugs was
calculated with the following formula:C= [A]c/[A]a+[B]c/[B]a.
If C is lower than 1, the two compounds tested have synergistic
effect; if C is>1, the two compounds tested have antagonist effect
and if C is 1 they are additive.
T. gondii and HFF Mitochondrial Membrane
Potential Measurements
The mitochondrial membrane potential was measured by the
safranine method according to Vercesi et al. (1998). Freshly
egressed T. gondii tachyzoites were filtered and washed twice
with intracellular buffer (125mM sucrose, 65mM KCl, 10mM
HEPES-KOH buffer, pH 7.2, 1mM MgCl2, and 2.5mM
potassium phosphate). After washing, the parasites were
resuspended in the same buffer at 109/mL. An aliquot of 50 µL
of this suspension was added to a cuvette containing Safranin
O, 2.5µM and Succinate 1mM in final volume of 2mL of
the intracellular buffer. The fluorescence was measured with
a Hitachi 7000 spectrofluorometer with settings Ex. 495/Em.
586. Once the baseline fluorescence was stable, 30µM digitonin
was added to permeabilize the parasites. Eighty five seconds
after permeabilization, the THQ derivatives, dissolved in DMSO,
were added. Five micromolars of FCCP (Carbonyl cyanide-4-
(trifluoromethoxy) phenylhydrazone) was used as an uncoupler
reference for calculations and its effect was considered 100%.
We used similar conditions for measuring the mitochondrial
membrane potential of mammalian cells with the following
changes: the mammalian cells were resuspended at 108/mL. We
also used 50 µL of this suspension for each experiment in a total
volume of 2mL. The substrate used for mammalian cells was
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5mM glutamate and 5mM malate. A higher concentration of
digitonin (50µM)was used to permeabilize themammalian cells.
The compounds were added at ∼400 s after permeabilization.
Each experiment was repeated at least three times in duplicates.
Statistical analysis, unpaired student t-test, was performed using
GraphPad Prism 8.0 (GraphPad Software, Inc., San Diego, CA).
Structure Activity Relationship (SAR) and
Comparison of Effect on Toxoplasma gondii and HFF
Enzyme Activity
The effects of changing R1 as 7-Et, 7-Me, 6-CF3, or 6-Me
on activity against RH strain tachyzoites, kinetic solubility,
and metabolic stability were compared. Kinetic solubility and
metabolic stability in human or murine liver microsomes were
measured. The hERG (human Ether-à-go-go-Related) liability
was also determined. The hERG gene (KCNH2) encodes
a protein Kv11.1, the alpha subunit of a potassium ion
channel. This channel conducts the rapid component of the
delayed rectifier potassium current, IKr, which is critical for
repolarization of cardiac action potentials. A reduction in
hERG currents from adverse drug effects can lead to long
QT interval syndromes. These syndromes are characterized by
action potential prolongation, lengthening of the QT interval
on surface EKG, and an increased risk for “torsade de pointes”
arrhythmias and sudden death. The MDCK-MDR1 Permeability
Assay was also performed. MDCK-MDR1 refers to the ability
of a compound to permeate across membranes of MDCK-
MDR1 (Madin Darby canine kidney [MDCK] cells with the
MDR1 gene [ABCB1], the gene encoding for the efflux protein,
P-glycoprotein (P-gp)) in vitro. Assessing transport in both
directions (apical to basolateral and basolateral to apical) across
the cell monolayers enables an efflux ratio to be determined. This
provides an indication as to whether a compound undergoes
active efflux (mediated by P-gp). This provides a prediction of
blood brain barrier (BBB) penetration potential/permeability and
efflux ratio. Effect in CACO-2 (Colon Adenocarcinoma cells) as a
permeability assay and on cytochrome P450 (CYP 450) were also
determined. CYP enzymes catalyze oxidative biotransformation
(phase 1 metabolism) of most drugs. CYP enzymes, bind to
membranes in a cell (cyto) and contain a heme pigment (chrome
and P) that absorbs light at a wavelength of 450 nmwhen exposed
to carbon monoxide. Metabolism of a drug by CYP enzymes is a
major source of variability in drug effect. These weremeasured by
Chem Partners. The relative effect on HFF and parasite enzymes
also were compared.
RPS131 Tachyzoites in Human Primary Brain
Neuronal Stem Cells in vitro for Transcriptomics and
Transcriptomics Analyses
Culture of Human Primary Brain Neuronal Stem Cells (NSC)
was as described (McPhillie et al., 2016; Ngô et al., 2017); T.
gondii RPS131 on RH strain background (Hutson et al., 2010)
was used to infect the NSC as described (McPhillie et al., 2016;
Ngô et al., 2017). RNA was isolated and prepared and used for
transcriptomic experiments as described (McPhillie et al., 2016;
Ngô et al., 2017). Briefly, NSC, initially isolated from a temporal
lobe biopsy (Walton et al., 2006) were infected with either wild-
type or RPS131 RH tachyzoites using biological duplicates at
a multiplicity of infection of 2:1 and incubated as previously
described Ngô et al. (2017). Eighteen hours post-infection,
extracellular parasites were washed out with cold PBS before
total RNA extraction. Further isolation of the mRNA fraction
was carried out with miRNeasy Mini Kit columns (Qiagen)
following manufacturer instructions and Illumina barcoded
mRNA sequencing libraries were constructed with TruSeq RNA
Sample Preparation Kits v2 (Illumina). Libraries were sequenced
as 100 bp single reads with Illumina HiSeq 2000 apparatus at a
sequencing depth of ∼3 Gbp per sample. Sequencing reads were
mapped to the human (release GRCh38) and T. gondii ME49
strain (ToxoDB release 13.0) reference genome assemblies with
hisat2 (Kim et al., 2015) and raw read counts were per gene
were estimated with HTSeq (Anders et al., 2015). Identification
of parasite genes that were differentially expressed between wild-
type and RPS131 parasites was performed with the R package
DESeq2 (Love et al., 2014) using a generalized linear model
likelihood ratio test. Identification of orthologous genes between
T. gondii and P. cynomolgi was carried out by best-reciprocal
matches between T. gondii and P. cynomolgi proteomes using
Blastp and a e-value cutoff of 1× 10−3. The list of Genes that are
differentially expressed between P. cynomolgi hypnozoites and
the liver-schizont stage was extracted from a previously published
study by Cubi et al. (2017). Gene set enrichment analysis was
carried out with the GSEA tool (Subramanian et al., 2005) using
T. gondii Gene Ontology and cell cycle gene sets developed by
Croken et al. (2014) and visualized with the Enrichment Map
application in Cytoscape (Su et al., 2014).
Toxoplasma gondii in vivo
Type II Parasites in vivo
IVIS
Balb/C mice were infected intraperitoneally (IP) with 20 × 103
T. gondii (Prugneaud strain expressing luciferase) tachyzoites.
Treatment began 2 h later with JAG21 (5 mg/kg) which was
dissolved in DMSO, administered IP in a total volume of 0.05mL.
Mice were imaged every second day starting on day 4 post
infection using an IVIS Spectrum (Caliper Life Sciences) for
minute exposures, with medium binning, 20min post injection
with 150 mg/kg of D-luciferin potassium salt solution.
Brain cysts
Brain cysts were searched for in paraffin imbedded tissue of
the surviving Prugneaud strain infected treated Balb/C mice in
the IVIS study, 30 days after infection which was 16 days after
treatment had been discontinued. All treated mice had survived.
There were no surviving untreated mice in those experiments.
In separate experiments, Balb/C mice were infected IP with
20 × 103 T. gondii Me49 strain tachyzoites. In these separate
studies of mice with established chronic infection, after 30 days,
IP treatment with JAG21 was begun each day for 14 days. JAG21
was dissolved in DMSO and administered IP in a total volume
of 0.05mL. In experiments when tafenoquine was administered
alone or with JAG21 in some groups 3 mg/kg tafenoquine
was administered once on day−1 from when JAG21 treatment
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was initiated. Cysts in brain were quantitated on day 30, 16
days after discontinuing JAG21. Immunoperoxidase staining was
performed. Parasite burden was quantitated in twoways. The first
was using a positive pixel count algorithm of Aperio ImageScope
software. Positive pixels were normalized to tissue area (mm2).
Briefly, automated quantitation was done by counting positive
pixels per square area. The entire brain in one section was
scanned for each mouse. The Cyst burden was quantitated as
units of positive pixels per mm2. The average ± S.E.M. numbers
of mm2 per slide quantitated was 30.2±1.6 square mm per mouse
for this quantification. Each highpower field of view shown in
Figure 5C is∼0.02 mm2 per field of view. Cysts on each slide for
each condition in two biological replicate experiments were also
quantitated by 2 separate observers independently and results
compared with automated counting, separately.
RPS13 1 in vivo
This G1 arrested parasite persists in tissue culture for prolonged
times in the absence of tetracycline (Hutson et al., 2010), but in
immune competent mice it cannot be rescued with teteracycline,
or LNAME (L-NG-Nitro arginine methyl ester, an analog of
arginine) used as an antagonist of nitric oxide synthase (NOS)
that inhibits NO production, or both together (Hutson et al.,
2010).
In pilot studies, herein, interferon γ receptor knockout mice
that were not treated were observed following infection. At 7 and
at 14 days following infection, spleen, and liver were removed
and immune peroxidase stained. At 14 days a group of mice
were treated with anhydrotetracycline and when a subset of these
mice died, their spleen and liver were removed and immune
peroxidase stained.
As in the pilot studies, this RPS13 1 parasite also was used to
infect interferon γ receptor knockout mice in a treatment study.
The design of this experiment with these immune compromised
mice is shown in Figure 6. In this separate study, groups of mice
were infected with RPS131. They were treated with tafenoquine
on day−1, or JAG21 for 14 days 2 h after infection, or the two
together with tafenoquine on day−1 and JAG21 for the first
14 days, or with diluent only for 14 days, as described above.
For the initial 14 days, no tetracycline was administered. After
that time tetracycline was administered. Mice were observed
each day. At the time they appeared to have substantial illness
or at the termination of the experiment they were euthanized,
tissues fixed in formalin and stained with hematoxylin and
eosin or immunoperoxidase stained and parasite burden
was assessed.
RH Challenge in a Study of Oral Administration of a
Novel Nano Formulation of JAG21
Nanoformulation of JAG21 for oral administration in
T. gondii studies
JAG21 was prepared using hydroxyethyl cellulose (HEC) and
Tween 80. Briefly, this dispersant solution containing 5 mg/mL
HEC and 2 mg/mL Tween 80 in water was prepared. Solid
JAG21 was added to 20 mg/mL, and the dispersion was
sonicated for 60 s using a Sonics vc50 probe-tip sonicator
set to 20 kHz to homogenize. Sonication was performed at
room temperature. Aliquots of the homogeneous dispersion
were frozen and lyophilized using a VirTis AdVantage freeze
drier. These aliquots were stored at room temperature for 5–
6 months. Prior to dosing, aliquots were reconstituted using
water. Controls containing no JAG21 were also prepared.
Following reconstitution with water, the dispersion was imaged
using a Nikon ECLIPSE E200 optical microscope set to 40x
magnification. The average particle size of the JAG21 dispersion
in HEC/Tween 80 was determined using an in-house image
analysis program. This novel method to stably formulate JAG21
was discovered after all other studies were completed and
this was the last experiment in this manuscript performed as
a consequence.
RH YFP challenge
For studies of the nano formulated JAG 21, this was administered
for 1 or 3 days by gavage in the doses shown in the results section.
These C57BL6 background mice received 2000 RH tachyzoites
IP. on day the first day of the experiment and peritoneal fluid
was collected 5 days later to quantitate fluorescence and numbers
of parasites.
Malaria Assays
Enzyme Assays
Methods for enzyme assays: Materials
P. falciparum 3D7 strain were obtained from the Liverpool
School of Tropical Medicine. Protease cocktail inhibitor was
obtained from Roche. Bradford protein assay dye reagent was
obtained from Bio-Rad. All other reagents were obtained from
Sigma-Aldrich. Decylubiquinol was produced as per Fisher et al.
(2009). In brief, 25mg of decylubiquinone were dissolved in 400
µL of nitrogen-saturated hexane. An equal volume of aqueous
1M sodium dithionite was added, and the mixture vortexed
until colorless. The organic phase containing the decylubiquinol
was collected, the solvent was evaporated under N2 and the
decylubiquinol finally dissolved in 100 µL of 96% ethanol
(acidified with 10mM HCl). Concentrations of decylubiquinol
was determined spectrophotometrically on a Cary 300 Bio
UV/visible spectrophotometer (Varian, UK) from absolute
spectra, using ε288−−320 = 8.1 mM−1.cm−1. Decylubiquinol was
stored at−80◦C and used within 2 weeks.
P. falciparum culture and extract preparation
P. falciparum strain 3D7 blood-stage cultures were maintained
by the method of Trager and Jensen (1976). Cultures contained
a 2% suspension of O+ human erythrocytes in RPMI 1640
medium containing L-glutamine and sodium carbonate, and
supplemented with 10% pooled human AB+ serum, 25mM
HEPES (pH 7.4) and 20µM gentamicin sulfate. Cultures were
grown under a gaseous headspace of 4% O2 and 3% CO2 in N2 at
37◦C. Cultures were grown to a parasitemia of 5% before use.
The protocol for the preparation of parasite extract was
adapted from Fisher et al. (2009). Free parasites were prepared
from infected erythrocytes pooled from five T75 flasks, by
adding 5 volumes of 0.15% (w/v) saponin in phosphate-buffered
saline (137mM NaCl, 2.7mM KCl, 1.76mM K2HPO4, 8.0mM
Na2HPO4, 5.5mM D-glucose, pH 7.4) for 5min, followed by
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three washes by centrifugation in RPMI containing HEPES
(25mM), and a final resuspension in potassium phosphate
buffer (50mM K2HPO4, 50mM KH2PO4, 2mM EDTA, pH7.4)
containing a protease inhibitor cocktail (Complete Mini; Roche).
Parasite extract was then prepared by disruption with a
sonicating probe for 5 s, followed by a 1min rest period on ice
to prevent the sample overheating. This process was performed
three times. The parasite extract was used immediately. The
protein concentration of the parasite extract was determined by
Bradford protein assay (Bio-Rad).
Pfbc1 native assay
P. falciparum bc1 complex cytochrome c reductase (Pfbc1)
activity was measured by monitoring cytochrome c reduction
at 550 vs. 542 nm using a Cary 300 Bio UV-Visible
Spectrophotometer (Varian, UK), using a protocol adapted
from Fisher et al. (2009).The assay was performed in potassium
phosphate buffer in a quartz cuvette and in a final volume of 700
µL. Potassium cyanide (10µM), oxidized cytochrome c (30µM),
parasite extract (100 µg protein), and compound/DMSO were
added sequentially to the cuvette, with mixing between each
addition. Test compounds were added to a final concentration
of 1µM. DMSO (0.1% v/v) and atovaquone (1µM), a known
malarial cytochrome bc1 complex inhibitor, were used as
negative and positive controls, respectively. The reaction was
initiated by the addition of 50µM decylubiquinol and allowed to
proceed for 3 min.
Malaria Parasite in vitro Studies
Malaria potency testing in vitro was performed using 4 different
P. falciparum strains, D6, TM91-C235, W2, and C2B. The D6
strain is a drug sensitive strain from Sierra Leone, the TM91-
C235 strain is a multi-drug resistant strain from Thailand, the
W2 strain is a chloroquine resistant strain from Thailand, and the
C2B strain is a multi-drug resistant strain with resistance against
atovaquone. These assays were performed as described below.
Compound Activity against Plasmodium falciparum
Compound activity against P. falciparum, was tested using
the Malaria SYBR Green I–Based Fluorescence (MSF) Assay.
The complete method for performing this microtiter assay
is described in previous work published by Plouffe et al.
(2008) and Johnson et al. (2007). In brief, this assay uses
the binding of the fluorescent dye SYBR Green I to malaria
DNA to measure parasite growth in the presence of 2-fold
diluted experimental or control. The relative fluorescence of the
intercalated SYBR Green I proportional to parasite growth, and
inhibitory compounds will result in lower observed fluorescence
compared to untreated parasites.
Cytotoxicity assays in parallel with P.falcipaum assays in
vitro
Toxicity studies also were performed with HepG2 cells (human
liver cancer immortal cell line derived from the liver tissue of a
15-year-old African American, ATCC R HB-8065TM) in parallel
with the studies of P. falciparum, with inhibitors in vitro, as
described in McPhillie et al. (2016).
P. berghei Causal Prophylaxis in vivo Model
P. berghei sporozoites were obtained from laboratory-reared
female Anopheles stephensi mosquitoes which were maintained
at 18 degrees C for 17–22 days after feeding on a luciferase
expressing P. berghei infected Swiss CD1ICR. Using a dissecting
microscope, the salivary glands were extracted from malaria-
infected mosquitoes and sporozoites were obtained. Briefly,
mosquitoes were separated into head/thorax and abdomen.
Thoraxes and heads were triturated with a mortar and pestle
and suspended in medium RPMI 1640 containing 1% C57BL/6
mouse serum (Rockland Co, Gilbertsville, PA, USA). 50–80
heads with salivary glands were placed into a 0.5mL Osaki
tube on top of glass wool with enough dissection media to
cover the heads. Until all mosquitoes had been dissected, the
Osaki tube was kept on ice. Sporozoites that were isolated
from the same batch of mosquitoes were inoculated into
C57BL/6, 2D knock-out, and 2D knock-out/2D6 knock-in
C57BL/6 mice on the same day to control for biological
variability in sporozoite preparations. On day 0, each mouse was
inoculated intravenously in the tail vein with∼10,000 sporozoites
suspended in 0.1mL volume. They were stained with a vital
dye containing fluorescein diacetate (50 mg/mL in acetone)
and ethidium bromide (20µg/mL in phosphate buffered saline;
Sigma Chemical Co, St. Louis, MO, USA) and counted in a
hemocytometer to ensure that inoculated sporozoites were viable
following the isolation procedure. Viability of the sporozoites
ranged from 90 to 100%.
Animals
The mice used in these experiments were albino C57BL/6 female
mice which were housed in accordance with the current Guide
for the Care and Use of Laboratory Animals (1996) under an
IACUC approved protocol. All animals were quarantined for 7
days upon arrival, and the animals were fed standard rodent
maintenance food throughout the study.
Test compounds, homogenization of JAG21 creating a
nanoformulation, and administration
Animals were dosed with experimental compounds based on
body weight. The suspension solution of orally administered
drugs were conducted in 0.5% (w/v) hydroxyethyl cellulose and
0.2% Tween 80 in distilled water. To insure the size of the
compounds in the dosing solution were under 50µM (measured
they were 4–6µM), the suspension was homogenized using a
homogenizer (PRO Scientific Inc, Monroe, CT, USA) with a
10mm open-slotted generator running at 20,000–22,000 rpm for
5min in an ice bath. The compounds were made fresh each day
and used immediately (always in <1/2 h). Stability beyond that
time was not determined. It was not anticipated that they would
be stable beyond that time.
Compounds were administered on 3 consecutive days (−1,
0, +1) relative to sporozoite infection or a single dose on day
0. Drug suspensions were administered to mice by oral gavage
using an 18 gauge intragastric feeder. For the 3 day dosing
regimen, compounds were administered at 0.625 mg/kg and for
the single dose regimen administered on day 0, compounds were
administered at 2.5 mg/kg.
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In vivo imaging
All of the in vivo bioluminescent imaging methods utilized
have been described previously. Briefly, JAG21 was administered
orally on days−1, 0, and 1 with respect to sporozoite inoculation.
All inoculated mice were imaged using the Xenogen IVIS-
200 Spectrum (Caliper Life Sciences, Hopkinton, MA, USA)
IVIS instrument at 24, 48, and 72 h post-sporozoite infection.
The bioluminescent imaging experiments were conducted by
IP injection of the luciferase substrate, D-Luciferin potassium
salt (Xenogen, California and Goldbio, St Louis, MO, USA),
into mice at a concentration of 200 mg/kg 15min before
bioluminescent images were obtained. Three minutes after
luciferin administration the mice were anesthetized using
isoflurane, and the mice were positioned ventral side up
on a 37◦C platform with continual anesthesia provided
through nose cone delivery of isoflurane. All bioluminescent
images were obtained using 5min exposures with f-stop =
1 and large binning setting. Photon emission from specific
regions was quantified using Living Image R© 3.0 software
(Perkin Elmer).
Additionally, blood stage parasitemia was assessed 3 days
after imaging was completed by treating small quantities of
blood obtained from tail bleeds with the fluorescent dye Yoyo-
1 measured by using a flow cytometry system (FC500 MPL,
Beckman Coulter, Miami, FL, USA) (Pybus et al., 2013; Marcsisin
et al., 2014).
Methods for Co-crystallization and Binding
Studies
Bovine Cytochrome bc1 Activity Assays
Bovine cytochrome bc1 inhibition assay was carried out in 50mM
KPi pH 7.5, 2mM EDTA, 10mM KCN, 30µM equine heart
cytochrome c (Sigma Aldrich), and 2.5 nM bovine cytochrome
bc1 at room temperature. 20mM inhibitors dissolved in DMSO
were added to the assay at a desired concentration without
prior incubation. The working concentration of DMSO in the
assay did not exceed 0.3% v/v. The reaction was initiated by
the addition of 50µM decylubiquinol (Abcam). The reduced
cytochrome c was monitored by the different absorption between
550 and 542 nm using extinction coefficient of 18.1 mM−1 cm−1
in a SPECTRAmax Plus 384 UV-visible Spectrometer. The initial
kinetic rate is determined as a zero-order reaction and used as the
specific activity of cytochrome bc1.
Bovine Cytochrome bc1 Purification Protocol
Preparation of crude mitochondria
Whole fresh bovine heart was collected after slaughter and
transported in ice. All work was carried out at 4◦C. Lean
heart muscle was cut into small cubes and homogenized in the
buffer composed from 250mM sucrose; 20mM K2HPO4; 2mM
succinic acid; 0.5mM EDTA. Buffer was added at a ratio of
2.5 L per 1 kg of muscle tissue. Ph of resulting homogenate was
adjusted to 7.8 using 2M Tris and PMSF protease inhibitor
was added to 0.1mM concentration. The homogenate was then
centrifuged in a Sorvall GS-3 rotor at 5,000 g for 20min. The
resulting supernatant was then transferred to a Sorvall GSA rotor
and centrifuged at 20,000 g for 20min. Obtained mitochondrial
pellet was washed in 50mM KPi (pH 7.5); 0.1mM PMSF buffer
before second centrifugation under the same condition. The
pellet was collected and sored at−80◦C for further use.
Solubilization of Membrane Proteins
The frozen mitochondria were thawed and re-suspended in
50mM KPi (pH 7.5); 250mM NaCl; 0.5mM EDTA; 0.1mM
PMSF buffer; a small sample was taken for quantification of total
mitochondrial proteins by BCA assay. The remaining sample was
centrifuged at 180,000 g in Beckman Ti70 rotor for 60min. The
pellet was re-suspended in the same wash buffer with the addition
1mg DDM per 1mg of protein and then centrifuged under the
same conditions for 60min. The pellet was discarded and the
supernatant was collected for ion exchange chromatography.
Purification of Cytochrome bc1
During purification the presence of protein was detected using
280 nm absorbance and the presence of heme was detected
using 415 nm Soret band peak and 562 nm absorbance. The
solubilized protein solution was applied onDEAE-Sepharose CL-
6B column (ca. 50mL, GE Healthcare) pre-equilibrated with
buffer A [50mM KPi (pH 7.5); 250mM NaCl; 0.01% w/v DDM;
0.5mM EDTA] and washed with 3 CV of buffer A. The protein
was eluted by linear gradient with buffer B [50mM KPi (pH
7.5); 500mM NaCl; 0.01%w/v DDM; 0.5mM EDTA]. Fractions
containing cytochrome bc1 were pooled and concentrated to
0.5mL using an Amicon Ultra-15 (Amicon, MWCO 100,000)
concentrator. Concentrated sample was applied to a Sephacryl-
S300 gel filtration column (ca. 120mL) pre-equilibrated in buffer
C [20mM KMOPS (pH 7.2); 100mM NaCl; 0.01%w/v DDM;
0.5mM EDTA] and eluted at a flow rate of 0.5 mL/min. Purified
cytochrome bc1 fractions were collected and concentrated to
40 mg/m. PEG fractionation with increasing concentration of
PEG4000 was used to precipitate cytochrome bc1. Precipitating
solution (100mM KMES pH 6.4; 10% PEG4000; 0.5mM EDTA)
was mixed with the protein to a desired PEG concentration. The
precipitated protein pellet was re-solubilised in buffer D (25mM
KPi pH 7.5, 100mM NaCl, 0.5mM EDTA, 0.015% DDM) and
dialysed in the same buffer in a centrifugal ultrafilter to remove
residual PEG. Five micromolars cytochrome bc1 was incubated
at 4◦C for 12 h with 50µM JAC21 (10-fold molar excess) diluted
from 20mM solution stock in DMSO.
Crystallization, Data Collection, and Refinement of
Cytochrome bc1–JAG21 Complex
The inhibitor-bound cytochrome bc1 was mixed with 1.6%
HECAMEG to the final protein concentration of 40 mg/mL.
Hanging drop method was used for crystallization. Two
microliter of final protein solution with 2 µL of reservoir
solution (50mM KPi pH 6.8, 100mM NaCl, 3mM NaN3,
10–12% PEG4000) was equilibrated over reservoir solution at
4◦C. The crystals were grown to 100µm within 4 days. The
single crystal was transferred in reservoir solution containing
increasing to 50% concentrations of ethylene glycol prior to
cryo-cooling in liquid nitrogen. X-ray data were collected from
single crystal PROXIMA2 beamline, SOLEIL light source, France
using DECTRIS EIGER X 9M detector at 0.9801Å wavelength
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up to 3.45Å resolution. Data were indexed and integrated
using iMosflm (Battye et al., 2011), and scaled using Aimless
(Evans, 2011). The starting model for refinement was 5OKD. All
ligands except co-factors were removed from the model prior to
refinement. Jelly-body refinement was carried out with Refmac5
(Murshudov et al., 2011). The inhibitor model was generated
by Jligand (Lebedev et al., 2012). The model was manually
edited in COOT (between cycle refinements. Data collection and
refinement statistics are shown in Supplemental Table 1A).
Cryo Electron Microscopy
Electron Microscopy and Image Processing
Cryo-EM was carried out as described in Amporndanai et al.
(2018). Briefly, 3 µL of sample at 5 mg/mL concentration were
applied to Quantifoil Cu R1.2/1.3, 300 mesh holey carbon grids
and plunge frozen using an FEI Vitribot (blot time 6 s, blot
force 6). Data were collected on an FEI Titan Krios with a
Falcon III direct electron detector operated in integrating mode
at 300 kV. Automated data collection was carried out using
EPU software with a defocus range of −1 to −3.5µm, and a
magnification of 75,000 × which yielded a pixel size of 1.065
Å. Data were collected for 72 h resulting in 5,356 micrographs.
The total dose was 66.4 e−/Å over a 1.5 s exposure which
was split into 59 frames. All of the processing was performed
in RELION 2.1 unless otherwise stated. The initial drift and
CTF correction was carried out using MOTIONCORR2 (Zheng
et al., 2017) and Gctf (Zhang et al., 2016), respectively. The
micrographs were examined and those with crystalline ice were
initially removed resulting in 2,960 micrographs. A subset of
∼2,000 particles were manually picked to generate 2D references
to facilitate auto-picking resulting in 439,009 particles. These
particles underwent an initial round of 2D classification with
those classes that displayed clear secondary structure detail being
taken forward to 3D classification and split into three classes.
Two of the three classes generated a high-quality cytochrome
bc1 reconstruction with secondary structure information clearly
visible. The particles from these two classes were recombined
to form the final datasets consisting of 211,916 particles in the
final reconstruction. The particles were 3D refined using C2
symmetry to produce a map with resolution 3.8 Å. The particles
also underwent movie refinement and particle polishing which
further improved the resolution of the map to 3.7 Å. A previously
refined EM structure for SCR0911 (pdb 6FO6) was fit into the
map using UCSF chimera and subsequently refined using phenix
with the correct ligand. The maps were then inspected manually
in COOT (Emsley and Cowtan, 2004) and the model corrected
for any errors in refinement and the placement of residues.
Statistical Analysis
A Pearson test was used to confirm a correlation between
increasing dose and increasing inhibition. An ANOVA and
subsequent pairwise comparison with Dunnett correction was
used to determine whether or not inhibition or toxicity at a given
concentration was statistically significant. Stata/SE 12.1 was used
for this analysis.
RESULTS
THQ Compounds Are Potent in vitro
Initially, a small library of seven compounds (Figure 1 [blue
and green font, Figure 1A] and Figure 2) were tested, and each
compound was tested at least twice against T. gondii tachyzoites.
JAG21 and JAG50 demonstrated effect below 1µM, and were
tested at lower concentrations. JAG50 and JAG21 were identified
as lead compounds given the IC50 values obtained were 33
and 55 nM, respectively. Correlation between concentration of
compound and inhibition of parasite replication (as measured by
fluorescence) was observed for all compounds except JAG46. The
relative effect on HFF and parasite enzymes were also compared,
with those marked ∗∗ in Figure 1A having the most effect on the
parasite enzyme activity relative to host HFF enzyme activity as
shown below in Figure 3.
A representative graph of these in vitro data is shown in
Figure 2A. Subsequently, a larger library of 54 compounds
was synthesized to ascertain structure-activity relationships
(SAR) (Figure 1B). Our primary aims were to block putative
metabolism of the terminal phenol ring of MJM170 and improve
the solubility across the compound series. Substituents were
generally tolerated at the meta and para positions on the phenol
ring (R1), similar to the trends observed in the ELQ series
(Vidigal et al., 2002; Doggett et al., 2012; McPhillie et al., 2016).
The incorporation of heteroatoms into the aryl rings of the
biphenyl moiety did not lead to improvements in solubility and
biological activity. Small substituents were tolerated at the 7-
position of the THQ bicyclic ring (Figure 1B; R1), improving
selectivity (see below, SAR) but not at the 6-position unlike
the ELQ series. In summary, overall, nitrogen atoms were
not tolerated in aryl ring (C) and the 4-position was optimal
for phenol substituent. Ultimately, no other compound had
all the advantages of JAG21, although some of these were
identified as potential back up compounds (marked with ∗∗),
with greater selectivity for the parasite relative to the mammalian
enzyme activity. Compound JAG21 displayed synergy against
RH strain tachyzoites with atovaquone (Figure 2C) but not with
pyrimethamine, although no antagonism was observed (data
not shown).
Cytotoxicity assays performed in parallel using HFF, WST-1
(Fomovska et al., 2012a,b), and HEP G2 cells demonstrated a
lack of toxicity at concentrations substantially in excess of the
concentrations effective against tachyzoites. Because T. gondii
grows inside cells, if a compound were toxic to host HFF
then it would make the compound appear to be spuriously
effective (Fomovska et al., 2012a,b), when in actuality only
toxicity for the host cell would be measured. Cytotoxicity to HFF
was therefore assessed for all compounds at 10µM. Results of
this experiment are in Figure 1A, toxicity column. A two-way
ANOVA and subsequent pairwise comparison found none of
the differences in absorbance, compared to the media-DMSO
vehicle controls, to be statistically significant (p > 0.05). Most of
these compounds are not toxic at 10µM (the limit of solubility)
and that cytotoxicity to cells can be attributed to DMSO in the
solution, not the compound. Dose response testing (IC50) was
performed with HEP G2 cells as described and the observed
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FIGURE 2 | JAG21 is potent in vitro against Toxoplasma gondii, tachyzoites and bradyzoites, and multiple drug resistant strains of P. falciparum. (A) JAG21 is
effective against RH-YFP tachyzoites, and does not harm human cells. Potent effect of JAG50 is also shown. A representative experiment is shown. N = triplicate
wells in at least 2 biological replicate experiments. Relative fluorescence units are shown on the vertical axis, where decrease in fluorescence compared to diluent
DMSO in media control indicates parasite inhibition (*p < 0.05). Horizontal axis indicates different treatment conditions: This shows results of testing of fibroblasts in
media (HFF), DMS0 control, positive control pyrimethamine and sulfadiazine(P/S), and concentrations of JAG21 and JAG50 utilized. Differences were not statistically
(Continued)
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FIGURE 2 | significant in the cytotoxicity assay (data not shown). (B) JAG21 is effective against EGS bradyzoites. Effect of JAG21 in reducing bradyzoites in HFF by
parasite strain EGS. HFF were infected by EGS and treated with JAG21 at concentrations indicated. Slides were stained with Dolichos Biflorus Agglutinin conjugated
with FITC (which stains the cyst wall) and DAPI, and observed with fluorescence microscopy. The red arrows point to the Dolichos enclosed organisms formed in
tissue culture. These were eliminated with treatment with JAG21. This experiment was performed >4 times. These experiments were performed with 3 different
observers reviewing slides at the microscope quantitating fields for each condition. Slides were also scanned and the scans of the slides were reviewed so all fields in
the entire slide were noted to be consistent. (C) Synergy of JAG21 and atovaquone against Rh-YFP tachyzoites in vitro. Isobologram comparing JAG21, atovoquone,
and JAG21 plus atovaquone demonstrates synergy. (D) THQs effective against drug resistant P. falciparum. Dose-response phenotypes of a panel of P. falciparum
parasite lines. IC50 values were calculated using whole-cell SYBR Green assay and listed as mean ± standard deviation of three biological replicates, each with
triplicate measurements. The D6 strain is a drug sensitive strain from Sierra Leone, the TM91-C235 strain is a multi-drug resistant strain from Thailand, the W2 strain is
a chloroquine resistant strain from Thailand, and the C2B strain is a multi-drug resistant strain with resistance against atovaquone. (E) Solubility and Stability in human
and mouse liver microsomes comparing MJM 170, JAG21, and JAG50. Performed by Chem Partners. (F) JAG21 CYP450 Inhibition, CACO-2, hERG, PPB, BBB
(MDCK-MDK1) efflux analyses. These were performed by Chem Partners and are as defined in the section Materials and Methods. RG38 is a structurally related
inactive THQ analog.
toxicity was: HEP G2 IC50 17.70µM (r2 = 0.97) for JAG21;
7.1µM (r2 = 0.98) for JAG50.
Lead compounds JAG50, JAG21, and others were tested
against EGS strain (Vidigal et al., 2002; Paredes-Santos et al.,
2013, 2018; McPhillie et al., 2016) tachyzoites and encysted
bradyzoites using methods described earlier (McPhillie et al.,
2016). We found a number of these compounds including JAG21
were highly effective against tachyzoites (RH-YFP; Fomovska
et al., 2012a) (Figures 1A, 2A,C) and bradyzoites of EGS (Vidigal
et al., 2002; Paredes-Santos et al., 2013, 2018; McPhillie et al.,
2016) (Figure 2B). For example, in a separate experiment
(data not shown) using immunofluorescence microscopy, the
following forms were observed: “true cysts” with a dolichos-
staining wall, “pseudocysts” or tight clusters of parasites, and
small organisms. If there were fewer than four parasites visible
in a cluster, organisms were counted individually (as “small
organisms”). A statistically significant reduction in the number of
true cysts and small organisms was observed at 1 and 10µM for
both compounds (p< 0.05, p< 0.005). Five hundred nanomolars
JAG21 treatment results in cultures where we do not see EGS
bradyzoites (e.g., Figure 2B).
Results against P. falciparum using methodology described
earlier (Trager and Jensen, 2005; Johnson et al., 2007; Plouffe
et al., 2008; McPhillie et al., 2016) also are shown in Figure 2D.
JAG 21 is potent against P. falciparum with IC50 values ranging
from 14 to 61 nM against a variety of drug sensitive and resistant
strains (McPhillie et al., 2016) including D6, TM91-C235, W2,
and C2B. The D6 strain is a drug sensitive strain from Sierra
Leone, the TM91-C235 strain is a multi-drug resistant strain
from Thailand, the W2 strain is a chloroquine resistant strain
from Thailand, and the C2B strain is a multi-drug resistant strain
resistant to atovaquone. Effects of other comparison compounds
are also shown in this table and range from 31 to 20,000 nM
(Figure 2D).
ADMET Superiority of JAG21
In vitro absorption, distribution, metabolism, excretion, and
toxicity (ADMET) analyses of the THQ compounds were
outsourced to ChemPartner Shanghai Ltd. ELQ-271 (synthesized
in-house) was tested as a comparison. THQs which were
potent inhibitors of T. gondii tachyzoites were assessed for their
kinetic solubility, metabolic stability in human, and mouse liver
microsomes (Figure 2E), hERG, and their ability to permeate
across MDCK-MDR1 cell membranes (in vitro measure of
blood-brain barrier (BBB) penetration potential/permeability).
Solubility, half-life, HERG, and BBB permeability/efflux results
are shown in Figure 2F. The aqueous solubility (PBS, pH 7.4)
of amorphous compounds JAG21 and JAG50 was 7 and 16µM,
respectively, which is improved over MJM170 (2µM) and ELQ-
271 (0.2µM). We also tested solubility of the microcrystalline
form of JAG21 and found that the solubility was 3.5µM. JAG21
was the most metabolically stable compound in human liver
microsomes (>99% remaining after 45min) compared with
other THQs and ELQ-271, although it displayed a much shorter
half-life of 101min in mouse liver microsomes. All THQs tested
in the MDCK-MDR1 system for blood brain barrier (BBB)
permeability (including MJM170, JAG21, and JAG50), exhibited
high permeability (Papp >10 × 106 cm/s) and low efflux (efflux
ratio<1.5).
THQs Potently Inhibit Parasite Cytochrome
bc1 (Cytbc1) Enzyme Activity
JAG21 is the most active of the initially tested THQs against T.
gondii Cytbc1, which also showed selectivity for the parasite over
the mammalian mitochondrial membrane potential (Figure 3).
Following the full SAR testing in vitro against tachyzoites, the
full set of compounds was tested against HFF; then the initial
compounds also were tested against the T. gondii and HFF
enzyme benchmarked against atovaquone, and ultimately the full
set of compounds was compared for effect against the T. gondii
and HFF enzymes.
Mitochondrial membrane potential measurements were
performed with permeabilized T. gondii tachyzoites in
suspension using safranin O, which loads into polarized
membranes [see section Materials and Methods in the
Supplemental Materials (Vercesi et al., 1998)]. T. gondii
tachyzoites were permeabilized with digitonin to allow the
mitochondrial substrate succinate to cross the membrane and
energize the mitochondrion. The fluorescence of safranin O,
which loads into energizedmitochondria was used tomeasure the
membrane potential. The energized state of the mitochondrion
is observed by a decrease in fluorescence (Figures 3A,C,E).
Trifluoromethoxy carbonylcyanide phenylhydrazone (FCCP)
was used to depolarize the membrane, which is observed as
an increase in fluorescence (Figures 3A,B). JAG21 depolarized
the membrane potential even at concentrations as low as 2 nM
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FIGURE 3 | Effect of JAG21, and other THQ compounds on mitochondrial functions of Toxoplasma gondii, Plasmodium falciparum and HFF-hTE RT (A). Maximum
mitochondrial membrane depolarization of JAG21, JAG39, JAG46, JAG47, JAG50, and Atovaquone (4µM) and FCCP (5µM). Digitonin was added where indicated
by the arrow to permeabilize cells and permit a necessary mitochondrial substrate (Succinate) to reach intracellular organelles. The addition of the indicated
compounds is shown by the second arrow. (B) Quantification of the depolarization shown in (A). The relative depolarization of each compound was normalized to the
depolarization by FCCP which was considered 100% depolarization. (C) Effect of various concentrations of JAG21 and Atovaquone on the mitochondrial membrane
(Continued)
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FIGURE 3 | potential measured as in (A). The first arrow indicates digitonin addition and the second arrow indicates the addition of compounds at the specified
concentration. (D) Quantification of the depolarization measured in (C). The relative depolarization of each compound was normalized to the depolarization by FCCP
(100%). (E) Mitochondrial membrane depolarization of HFF-hTERT in suspension by JAG21 and atovaquone. The first arrow indicates the addition of digitonin, and
the second arrow indicates addition of the indicated compounds at the indicated concentration. (F) Quantification of the depolarization measured in (E). The relative
depolarization of each compound was normalized with the depolarization by FCCP, which was considered 100%. (B,D,E) X ± S.D., N = 3 independent experiments.
Statistical analysis (unpaired student t-test) was performed using GraphPad Prism 8.0 (GraphPad Software, Inc., San Diego, CA). **P < 0.01. ***P < 0.001. (G)
JAG21, JAG99, and MJM210 (1µM) inhibited P. falciparum cytochrome c reduction. Vehicle (DMSO)/atovaquone (1µM) were negative/positive controls, 1,290
respectively. X ± S.D., N = 4 independent experiments.
(Figures 3C,D). JAG21 and Atovaquone had similar effects
on the mitochondrial membrane potential (Figure 3D). Other
compounds like JAG46 and 47 showed almost no effect at doses
as high as 4µM (Figures 3A,B). JAG50 showed depolarizing
activity at doses of 200 nM and higher. The effect of these THQ
compounds against the T. gondii mitochondrial membrane
potential was greater than the effect on the human foreskin
fibroblast mitochondrial membrane potential (Figures 3E,F).
This is consistent with the observation that JAG21 is less toxic
against human Telomerase reverse transcriptase immortalized
(hTERT) HFF cells than atovaquone. We had newly created
THQ compounds, not yet characterized fully, that show even less
toxicity to the human fibroblast cytochrome b/c complex marked
with ∗∗ in Figure 1A. These could be developed in a second phase
of our program, were reductions in toxicity needed. However,
as data presented herein demonstrates, there are significant
advantages in the ADMET properties of JAG21, and its dramatic
efficacy in vivo,without toxicity. There may be no need to further
develop any of those potential additional leads.
Enzyme reduction of cytochrome c by P. falciparum parasite
extract (Fisher et al., 2004, 2009) is mediated by P. falciparum
bc1 complex cytochrome c reductase (Pfbc1) enzyme. All three
compounds tested (1µM) significantly inhibited the reduction
of cytochrome c by the P. falciparum parasite extract (JAG21 =
86.4 ± 3.2; JAG99 = 81.3 ± 6.0; MJM170 = 69.7 ± 11.3% of the
atovaquone response, Figure 3G. Additional data demonstrated
selective effect on P. falciparum enzyme compared with bovine
enzyme (data not shown).
Binding, Co-crystallography,
Pharmacophore, and Cryo-electron
Microscopy Studies Demonstrate
Selectivity
In binding assays and in co-crystallography (Emsley and Cowtan,
2004; Emsley et al., 2010; Battye et al., 2011; Laskowski
and Swindells, 2011; Murshudov et al., 2011; Lebedev et al.,
2012; Capper et al., 2015; McPhillie et al., 2016; Zhang
et al., 2016; Zheng et al., 2017; Amporndanai et al., 2018),
JAG21 has lower binding affinity to bovine cytochrome bc
in comparison with previous compounds that we have tested.
JAG21 “inhibits” Cytbc1 but not fully, indicating that it will
be less toxic for mammalian (bovine/human) cyt bc1 than
the apicomplexan enzymes (Figure 4A). The electron density
map in the Qi site of bovine cytochrome bc1complex with
JAG21 (Supplemental Table 1,Data Collection Statistics) reveals
an additional electron density, which allowed unambiguous
positioning of the inhibitor (Figure 4B). No additional electron
density was found within the Qo site. After the refinement, 2Fo-
Fc electron around JAG21 becomes clearer (Figure 4C). The
second aromatic ring in the tail group of the compound is less
defined due to high flexibility introduced by the oxygen linker.
The quinolone head of JAG21 is held between Asp228 and
His201 and adapted the same conformation as 4(1H)-pyridone
(GSK932121) (Capper et al., 2015) (Figure 4D) and tetrahydro-
4(1H)-quinolone (MJM170) (McPhillie et al., 2016) (Figure 4E)
by directing the NH group to His201 and the carbonyl group to
Asp228. The carbonyl of the quinolone head and OG1 atom of
Ser35 are within 3.0 Å distance that allows hydrogen bonding
and enhances the binding affinity to the bovine enzyme. The
3-diarylether tail extends along a hydrophobic channel defined
by Gly38, Ile39, and Ile42. The trifluoromethoxy group at the
phenoxy ring points toward Met190 and Met194 (Figure 4F).
CryoEM studies of the complex also demonstrate reasons for
selectivity. In Figure 4F, the density suggests that the inhibitor
can adopt two different binding poses as observed previously in
the cryo-EM structure of GSK932121 (Capper et al., 2015). The
binding pose shown in yellow, which has the strongest density,
agrees with the crystal structure and has the trifluoromethoxy
group pointing toward Met194. However, there is additional
density which could result from a second binding pose (green)
in which the trifluoromethoxy group points toward Asp228
(McPhillie et al., 2016). Figure 4F shows GSK932121 pyridone
(PDB:4D6U) (Figure 4G) MJM170 quinolone (PDB:5NMI). The
EMmap has been deposited at the EMDB (EMDB-11002).
JAG21 Is Potent in vivo
In vivo studies of JAG21 against T. gondii demonstrated
high efficacy in a variety of settings. JAG21 at 5 mg/kg/day
administered IP improves well-being and eliminates illness and
T. gondii Type II Prugneaud luciferase tachyzoites completely in
luminescence studies (Figure 5A). Further, treatment beginning
on day one after infection results in no cysts being found in
brains of these mice treated for 14 days with 5 mg/kg/day of
JAG21, when brains were evaluated 30 days after stopping JAG21
treatment in two replicate experiments. Treatment beginning
on day 30 after initiation of infection with Type II Me49
parasites results in marked, statistically significant reduction in
normal appearing cysts, free organisms, and immunoperoxidase
stained cysts detected by automated imaging of scanned slides
(Figures 5B,C, p < 0.03 experiment 1: p < 0.01 experiments
1 and 2 together, Supplemental Figure 1). The automated
analysis confirmed results from the blinded microscopic visual
quantitation of cysts and free organisms in slides by two
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FIGURE 4 | Binding studies of JAG21 to bovine bc1. (A) Bovine Cytbc1 activity assays showing 36 and 63% inhibition at 0.1 and 1µM concentration of JAG21,
respectively. N = at least 2 biological replicate experiments with similar results. (B) The Cytbc1 structure presented in cartoon style with clear omit (Fo-Fc) electron
density map for the bound JAG21 compound only in the Qi site showing selectivity within the binding pocket. Qi and Qo sites are marked by black ellipsoids. (C) The
bound JAG21 compound (orange) within the Qi site with corresponding (2Fo-Fc) electron density map contoured at 1 σ level as gray mesh. The residues which make
close interactions with the bound inhibitor are shown in stick format and labeled. (D) 2D pharmacophore analysis of JAG21 binding pocket produced using Ligplot+
LS-2011. Hydrophobic interactions are shown as red spikes, hydrogen bond with Ser35 is shown by green dashes. (E) Cryo-EM derived structure of the Cytbc1
bound JAG021 structure with corresponding density map contoured at 3 σ level suggesting two different positions for the head group represented by two regions of
density shown as yellow mesh. The Cytbc1 structure bound to the pyridone GSK932121 (PDB:4D6U) (F) and quinolone MJM170 (PDB:5NMI) (G) in the Qi site. Haem
and compounds are shown as colored sticks, Fe ion as orange sphere and hydrogen bonding as black lines. Hydrogen bonding with Ser35 is shown as black dashes.
Terms JAG021 and JAG21 used interchangeably for this same compound.
observers. Adding tafenoquine or primaquine to treatments of
active plus dormant malarias (St Jean et al., 2016; Lacerda
et al., 2019; Llanos-Cuentas et al., 2019) is partially effective
against both active and dormant phase plasmodia, when neither
treatment of active nor dormant disease alone is effective
for either in vivo. We developed experiments based on these
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observations where experiments with tafenoquine alone or with
JAG21 alone was used in the experiments with established cysts
with immune competent mice. This was to determine whether
tafenoquine might add to efficacy of JAG21. The efficacy of
treatment with JAG21 alone was so robust (Figure 5B), that
no additive effect was seen, or could have been detected, by
adding Tafenoquine to JAG21. Efficacy was shown when data
were analyzed as separate groups, i.e., control vs. JAG21 alone
(p < 0.03) or control vs. JAG21 plus tafenoquine, or grouping
the JAG21 and JAG21 plus tafenoquine results as “untreated” vs.
“treated” (p < 0.01). Analysis shown combining both treatment
groups from two replicate experiments showed similar results (p
< 0.01, Figure 5B), and when results from replicate experiments
were grouped (Supplemental Figure 1). In Figure 5C the control
mice had cysts with usual morphology (Top two panels), whereas
treated mice had very few morphologically recognizable usual
cysts that were immunostained (bottom panels).
A nano formulation homogenized (<6µM) was used
effectively orally for the P. bergheii experiments, further,
importantly, was effective in the single oral dose causal
prophylaxis in 5 C57BL/6 albino mice at 2.5 mg/kg dosed on
day 0, 1 h after intravenous administration of 10,000 P. berghei
sporozoites was completely protective. In addition, 3 dose causal
prophylaxis treatment in 5 C57BL/6 albino mice at 0.625 mg/kg
dosed on days −1, 0, and +1 also was completely protective. A
representative experiment at a higher dose (5 mg/kg) is shown,
but all experiments with the oral dosing regimen with the
nanoformulation specified above showed 100% survival 30 days
post infection with P. berghei, where all liver and blood stage
parasites were eliminated (Figures 5D,E) demonstrates not only
efficacy of JAG21 against the three life cycle stages of P. berghei,
but also demonstrates the efficacy of oral administration of the
nanoformulation when used immediately, at a low dose.
G1 Arrest, Persisters, Companion
Compounds
In mice that were treated with JAG21 early after infection
(Figure 5A) we could find no residual immunostaining for T.
gondii in brain tissue of any mice. This suggests that very
early treatment could prevent established, chronic infection, for
example in epidemics such as those that occurred in Victoria,
Canada, the U.S.A., and Brazil. In mice with established cysts,
following treatment with JAG21, we occasionally saw a small
number of cysts (Figure 5B) and amorphous immunostained
structures (Figure 5C, bottom panels). This was reminiscent of
persistence in some malaria infections (Cubi et al., 2017) and
abnormal immunostained structures we previously identified
with a conditional, tetracycline-on regulatable, mutant T. gondii
(Hutson et al., 2010 and Supplemental Figure 2). In this
1RPS13 tachyzoite, small ribosomal protein 13 can be regulated,
depending on whether anhydrotetracycline (ATc) is absent or
present, leading the ATc responsive repressor to be on or off
response elements engineered into the promoter (Hutson et al.,
2010). 1RPS13 replicates with ATc present and is arrested in
G1 when ATc is absent in HFF cultures (Hutson et al., 2010).
The dormant parasite could persist for extended periods (Hutson
et al., 2010). The parasite could be rescued from its dormant—
ATc state by adding ATc, months after removing tetracycline
from infected HFF cultures, although it could not be rescued
in immunocompetent mice with LNAME and ATc when tested
1 week after infection (Hutson et al., 2010). We wondered if
this type of dormant organism could form in vivo, whether it
could contribute in a biologically relevant way to dormancy and
recrudescence, similar to the malaria hypnozoite (Cubi et al.,
2017; Muller et al., 2019), and whether JAG21 might be able to
eliminate it, or whether a companion compound effective against
this form might be needed or work in conjunction with JAG21 if
needed. To begin to address these questions and to investigate
how close the T. gondii 1RPS13 -ATc phenotype might be to
the malaria hypnozoite, we compared the transcriptome of T.
gondii 1RPS13 in human, primary, brain, neuronal stem cells
+/– ATc to the recently published P. cynomolgi hypnozoite
transcriptome, established with single cell RNA sequencing in
laser captured organisms (Cubi et al., 2017). This analysis
identified 28 orthologous genes with similar expression pattern
in both T. gondii 1RPS13 -ATc and P. cynomolgi hypnozoites,
including the downregulation of rps13 and upregulation of
the eukaryotic initiation factor-2α kinase IF2K-B, a protein
involved in translational control in response to stress (Cubi
et al., 2017) (Figure 6A). Further. assessment of the T. gondii
1RPS13 transcriptome in the absence or presence of ATc showed
upregulation of additional IF2K members, 25 Apetela (AP) 2
transcription factors and a number of genes that participate as
protein ubiquitin ligases, and in trafficking as well as in RNA
binding, and GCN1 (Supplemental Table 2). None of them,
except for AP2VIIa-7, have been shown to be upregulated nor
downregulated during differentiation to bradyzoites. Gene set
enrichment analysis showed that in the absence of ATc, the
T. gondii 1RPS13 transcriptome is enriched in genes typically
expressed during G1, confirming previous results indicating that
downregulation of rps13 arrests the parasite at this stage of
the cell cycle (Figure 6B) (Hutson et al., 2010). Moreover, a
number of biological processes are downregulated without ATc,
including protein synthesis and degradation as well as energy
metabolism (Figure 6B). Noteworthy, some gene ontology (GO)
terms enriched in T. gondii1RPS13 -Tc are also overrepresented
in the P. cynomolgi hypnozoite (stars in Figure 6D). Further,
without ATc the transcriptome of T. gondii1RPS13 is compatible
with a parasite transitioning from an active replicating form
to a dormant stage, reflected by the downregulation of genes
typical of the S and M stages of the cell cycle, and of
genes that participate in energy metabolism and virulence
(Figures 6B,D, Supplemental Table 2, Supplemental Figure 2).
It has been reported that with treatment of active forms of
malaria, hypnozoites still persist, and recrudesce later (Hutson
et al., 2010; St Jean et al., 2016; Cubi et al., 2017; Lacerda
et al., 2019; Llanos-Cuentas et al., 2019). Also, compounds
that target cytochrome b/c were not effective against malaria
hypnozoites. If primaquine or tafenoquine, which do not treat
the active Plasmodium vivax parasites, were added in vivo,
hypnozoites have been shown not to recrudesce, or do so less
often (St Jean et al., 2016; Lacerda et al., 2019; Llanos-Cuentas
et al., 2019). Testing with primaquine or tafenoquine could
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FIGURE 5 | JAG21 is a mature lead that protects against Toxoplasma gondii and Plasmodium berghei in vivo. (A) JAG21 treatment for 14 days protects against T.
gondii tachyzoites in vivo. Tachyzoite challenge with Prugneaud luciferase parasites imaged with leuciferin using IVIS demonstrates that treatment with JAG21
eliminates leuciferase expressing parasites and leads to 100% survival of JAG21 treated infected mice. No cysts were found in brains of mice at 30 days after infection
when they have been treated with JAG21 for the first 14 days after infection. There were 2 biological replicate experiments with 5 mice per group with similar results.
(B) JAG21 and JAG21 plus tafenoquine markedly reduce Me49 strain brain cyst numbers in vivo in Balb/C mice at 30 days after infection. Parasites were quantitated
by scanning the entire immunoperoxidase stained slide in an automated manner and by two observers blinded to the experimental treatment using microscopic
evaluation. In each of two experiments, the numbers of mice per group were as follows: Experiment 1 had 4 diluent controls, 5 JAG21, 4 JAG21/Tafenoquine treated
mice; and Experiment 2 had 5 diluent controls, 5 JAG21, 3 JAG21/Tafenoquine treated mice. Immunoperoxidase staining was performed. Parasite burden was
quantitated using a positive pixel count algorithm of Aperio ImageScope software. Positive pixels were normalized to tissue area (mm2). Quantification was by
counting positive pixels per square area. The entire brain in one section was scanned for each mouse. The parasite burden was quantitated as units of positive pixels
per mm2. The average ± S.E.M. numbers of mm2 per slide quantitated was 30.2±1.6 mm2 per mouse for this quantification. Each high power field of view shown in
(Continued)
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FIGURE 5 | C is ∼0.02 mm2 per field of view. A representative single experiment is presented and the data from the two experiments analyzed together also
demonstrated significant differences between the untreated and treated groups (p < 0.01; Supplemental Figure 1). (C) Microscopic evaluation of the slides reveal
effect of JAG21 and JAG21 plus tafenoquine having the same pattern as the automated quantitation of immunoperoxidase stained material. There are usual
appearing cysts in the DMSO control untreated mice as shown in the top panels, and rare cysts in the treated mice with most of the brown material appearing
amorphous (bottom panels). (D) JAG21 nanoformulation dosages administered to P. berghei infected C57Bl6/albino mice compared with vehicle control. Design of
single dose and 3 day dose experiments. (E) JAG21 nanoformulation cures P. berghei sporozoites (left panel), blood (middle panel), and liver stages, leading to 100%
survival (right panel). This is with oral administration of a single dose of 2.5 mg/kg or 3 doses at 0.625 mg/kg. Single dose causal prophylaxis in 5 C57BL/6 albino
mice at 2.5 mpk dosed on day 0, 1 h after intravenous administration of 10,000 P. berghei sporozoites. Shown is 3 dose causal prophylaxis treatment in 5 C57BL/6
albino mice at 0.625 mpk dosed on days −1, 0, and +1. Representative figure showing survival (right panel), luminescence (left panel), and parasitemia quantitated by
flow cytometry (middle panel) for 5 mg/kg.
only be performed in vivo, as activity against the hypnozoite
requires hepatic metabolism of primaquine or tafenoquine (St
Jean et al., 2016; Lacerda et al., 2019; Llanos-Cuentas et al.,
2019). Tafenoquine is not active in tissue culture which is
consistent with the findings that these compounds require
hepatic metabolism. To establish a parallel in vivo system, we
studied immune compromised mice (Interferon g receptor
knockout mice with the knockout in the germline) infected with
1RPS13 herein. Although in immune competent mice 1RPS13
does not recrudesce with ATc treatment initially, beyond 3
days after infection, we found that when ATc was added after
treatment of the immune compromised mice with JAG21 dosed
intraperitoneally for 14 days, the dormant 1RPS13 parasite
could still recrudesce after JAG21 treatment was discontinued
and tetracycline added (Figure 6C and Supplemental Figure 2).
Consistent with adding tafenoquine to treatment of P.vivax
malaria with chloroquine where both medicines together were
partially effective against the active and hypnozoite forms, the
combination of JAG21 and tafenoquine had a modest effect
together on transiently improving survival time when ATc
was added when compared with JAG21 or tafenoquine alone
(Figure 6C and Supplemental Figure 2). The trend in the result
seems similar to the malaria infections where hypnozoites form,
although protection was not as robust, as in the malaria model,
and we did not achieve complete, durable protection against
1RPS13. These results in Figure 6C and Supplemental Figure 2
suggest: (a) In G1 arrested organisms that begin as tachyzoites,
they can persist in vivo even if their morphology as parasites is
difficult to discern; (b) Treatment with JAG21+Tafenoquine can
prolong time to death more robustly than other treatments; (c)
But, in these immune compromised mice at this dosage regimen
this treatment did not robustly, durably protect these mice from
death later; (d) In these immune compromisedmice, whether this
lack of complete protection was because of immune compromise,
or less than optimal duration of treatment, or suboptimal dose or
timing of treatments, or that this G1 arrested organism is harder
to treat, remains to be determined in future studies. The modest
efficacy of the two compounds, administered together, suggests
that treating both tachyzoites and the G1 arrested organisms
is important. This seems similar to P. cynomogli and P. vivax
treatment with tafenoquine and chloroquine studies, which also
showed efficacy but was not completely successful in preventing
relapse. At the time this study was performed, formulation
and dosing (including duration and timing) had not yet been
optimized formally for the T. gondii model. P. vivax treatment
requires chloroquine to treat blood schizonts and tafenoquine
to treat hypnozoites. Treatment in man, per the FDA approved
label, consists of a single dose of 300mg on day 1 co-administered
with chloroquine treatment on days 1 or 2. Both medicines have
long half-lives in humans. This treatment was relatively effective
in humans, with about a 30% recurrence rate.
Sinai et al. have demonstrated heterogeneity in the phenotypes
of organisms within established cysts. Their work found
bradyzoites within cysts are not uniform with regard to
their replication potential (Watts et al., 2015), mitochondrial
activity (Sinai, unpublished), and levels of the glucose storage
polymer amylopectin (Sinai, unpublished). These properties of
bradyzoites (Watts et al., 2015), and properties of tissue cysts
that vary during the course of infection, demonstrated that
there are unappreciated levels of complexity in the progression
of chronic toxoplasmosis (Watts et al., 2015). The analysis
(Figure 6D) of the 1RPS13 infected NSC suggests molecular
targets that are modified in this G1 arrested 1RPS13 parasite
as shown in Figure 6D and Supplemental Table 2. In the future,
with formulation and pharmacokinetics of JAG21 optimized, it
will be of interest to determine whether JAG21 can eliminate
these organisms and any residual structures as in Figure 6C,
or whether adding synergistic compounds such as atovaquone
(Figure 4B) or antisense effective against these upregulated
molecular targets, such as kinases, ATPases, AP2s (Figure 6D
and Supplemental Table 2), or a newly recognized bradyzoite
master regulator of differentiation might be effective alone or
might be synergistic with JAG21 against this 1RPS13, as well
as the conventional recognized tachyzoite and bradyzoite life
cycle stages. Chen et al. reported in the transcriptomes of
established bradyzoite in vivo cysts that EIF2kinase of stressed
parasites is present (Chen et al., 2018), but we have not found
other overlap of Chen’s transciptome with P cynomogli or
1RPS13 transcriptomes. Others have described EIF2kinase and
stress granules only in transitioning or extracellular parasites
(Watts et al., 2015). Bradyzoites within tissue cysts are not
monolithic. Thus, in future studies, single cell RNA sequencing
of bradyzoites obtained by laser capture of bradyzoites in
vivo, defined on the basis of their physiological state, may be
needed to determine whether a transcriptome signature similar
to 1RPS13 is sometimes present. This could be linked to
morphologic/immunostaining features that might functionally
distinguish them to define the character of a hypnozoite-like
state in T. gondii. We noted heterogeneity of parasite phenotype,
even in the same vacuoles, in our earlier IFA and electron
microscopic characterization of G1 arrested 1RPS13 in HFF
(Hutson et al., 2010). Heterogeneity also was found very recently
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FIGURE 6 | Toxoplasma gondii 1RPS13 transcriptome during Primary Human Brain Neuronal Stem Cell (NSC) infection and in-vivo susceptibility to JAG21 and TAF
treatment are reminiscent of literature findings with malaria hypnozoites. (A) P. cynomolgi-T. gondii best reciprocal match genes significantly upregulated (red) or
downregulated (blue) in P. cynomolgi hypnozoites compared to liver-schizont stage and in 1RPS13 after downregulation of rps13 gene expression (p ≤ 0.05, FDR ≤
0.2). (B) Gene-set enrichment analysis of 1RPS13 +/– Tc. Blue and red nodes denote gene-sets enriched in presence or absence of Tc, respectively. Node diameters
are proportional to number of genes belonging to corresponding gene-sets. Edge thickness is proportional to number of genes shared between connected nodes. (C)
Survival rate of mice infected with 100,000 1RPS13 followed by treatment with diluent, JAG21, tafenoquine (TAF) or the two together (JAG21/TAF). Then tetracycline
was added at 14 days. The combination of the two compounds resulted in improved time of survival (p < 0.03, Experiment 1; p = 0.08 Experiment 2, p = 0.002
Experiment 1+2). The full data are presented in the box below the image in (C). (C) Rx refers to treatment of mice with diluent (DMSO), Tafenoquine (TAF), or JAG21,
or JAG21 and TAF. 1RPS13 is referred to as RhRPS131 in the title of the box in (C). In Supplemental Figure 2, histological preparations that are
immunoperoxidase stained for T. gondii antigens from a pilot study were prepared (Supplemental Figure 2). These are images, in Supplemental Figure 2 of liver
and spleen from IFN γ receptor knock out mice without treatment on days 7 and 14 after infection. In those mice without any treatment there was amorphous brown
immunoperoxidase stained material in Supplemental Figure 2A. When tetracycline (aTet) was administered on day 14 after infection in drinking water, with tissues
obtained and immunostained for T. gondii antigens from mice that died or became very ill, organisms that were clearly recognizable could be seen
(Supplemental Figures 2B–E). Design of the treatment experiment with control DMSO diluent, JAG21 alone, Tafenoquine alone (TAF) or the two together (JAG/TAF)
with full data for each of the groups and with the composite analysis from replicate experiments, including numbers of mice, are shown in
Supplemental Figures 2C,D. Supplemental Figures 2C,D shows prolongation of survival time, but there is not durable protection against 1RPS13 in these
immune compromised mice treated with JAG21/TAF as described. This is summarized in C to demonstrate early prolongation of survival time with the detailed data in
Supplemental Figure 2. (D) Gene ontology enrichment analysis of 1RPS13 +/–Tc. Node and edge conventions are the same as in (B). There were at least 2
biologic replicates of each experiment.
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FIGURE 7 | Oral nanoformulation of JAG21 potently protects against 2000 highly virulent RH strain tachyzoites given intraperitoneally. (A) Following sonication
produces nanoparticles of ∼2.86µM. (B) Single oral dose of 10 mg/kg reduced intraperitoneal tachyzoites measured by RH YFP expression and counting with
hematocytometer (p < 0.03). (C) Three daily 10 mg/kg doses markedly and significantly reduces intraperitoneal parasite burden measured as fluorescence and by
hematocytometer on the fifth day (p < 0.001). No compound was administered after the third day. N = at least 2 biological replicate experiments with 5 mice per
group with similar results.
in tachyzoites and bradyzoites created by alkaline conditions in
culture across the cell cycle in vitro in HFF, using single cell RNA
sequencing (Xue et al. Biorx, 6/3/2019 in press). These authors
also noted that what had been interpreted as “noise” earlier was
found actually to be signal in a more complex environment.
These authors suggest that such heterogeneity might make
developing curative treatments more complex. Our analysis of
JAG21 effects and the 1RPS13-ATet knockdown herein begin
to help address this question: We noted that consistent with
heterogeneity in our IFAs, in our comparison with the Xue et al.’s
heterogeneous P1-6 clusters analysis, we found that most of
the up- or down-regulated genes are within P3-P5 tachyzoite
clusters. Also, consistent with the heterogeneity we observed in
our G1 arrested 1RPS13 -ATet comparison, 1RPS13 has a drop
in SAG1 and elevated SRS44 that is consistent with a brady-like
phenotype. BAG1 expression was too low overall to draw any
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conclusion about BAG1. It is also noteworthy that in our -ATet
relative to +Atet conditions in primary, human, brain, neuronal
stem cells, the master regulator of bradyzoite differentiation is
slightly overexpressed (Log2 Fold Change=0.7, adjusted p =
0.043). Although JAG21 is highly potent against tachyzoites and
bradyzoites, it did not eliminate every long-established encysted
bradyzoite or -ATet1RPS13 completely either in vitro or in IFNγ
knock-out mice in vivo. Consistent with heterogeneity, herein
JAG21 treatment of1RPS13 and transcriptomics analyses define
a metabolically quiescent, persister, “stasis” state that is reversible
even after substantial periods of dormancy. These observations
contribute to conceptual and functional understanding of both
Plasmodia species and T. gondii infections and molecular
mechanisms whereby “persisters” might be eliminated.
An Oral Nanoformulation Is Potent Against
Virulent RH
To further develop JAG21 for practical, clinical use, our next step
was to make a formulation that is stable at room temperature,
and would be effective when administered orally: Following a
number of unsuccessful alternative methods (data not shown),
a dispersion of JAG21 was prepared using hydroxyethyl cellulose
(HEC) and Tween 80. This new formulation method is described
in the Materials and Methods. When this dispersion was imaged
using a Nikon ECLIPSE E200 optical microscope set to 40x
magnification, the average particle size of the JAG21 dispersion in
HEC/Tween 80 was determined using an in-house image analysis
program and was found to be 2.85µm (Figure 7A). Material
was re-sonciated the same way just prior to administration after
being stored for 6 months and retained the same properties
(Figure 7A) when imaged. Following administration of 2,000
highly virulent RH Strain tachyzoites intraperitoneally, the oral
nanoformulation was administered by gavage using a 21 gauge
needle. This was given either (1) as a single dose of 5, 10, or 20
mg/kg, or (2) three daily doses of 10 mg/kg given for the first
3 days after infection. After 5 days the RH strain tachyzoites in
peritoneal fluid of each mouse were quantitated by measurement
of YFP they expressed using a fluorimeter and by quantitating
parasites present in peritoneal fluid using a hemocytometer.
Parasite burden was reduced by ∼60% 5 days later following the
single doses of 10 and 20 mg/kg (representative experiment with
10 mg/kg shown in Figure 7B; p < 0.03) and markedly reduced
with three doses of 10 mg/kg administered on each of the first
3 days after intraperitoneal injection of the virulent RH strain
tachyzoites (Figure 7C, representative experiment, p < 0.001).
This is the proof of principle that will facilitate media milling,
dispersant, and a self disintegrating tablet in the future. JAG21
has real promise as a mature lead compound to treat both T.
gondii and Plasmodium species infections.
DISCUSSION
T. gondii infections are highly prevalent and the impact of this
disease can be devastatingly severe. Current treatments have
toxicity or hypersensitivity side effects. New compounds that are
without toxicity or hypersensitivity, and that are highly active
against tachyzoites would be of considerable clinical usefulness.
Further, no medicines are active against the encysted stage or
definitively curative. In addition, malaria is lethal for 1 child
every 11 s and a threat to travelers going to endemic areas.
Development of drug resistance also increases the need for new
anti-malarial compounds. Our goal in this work herein was
to identify compounds highly effective against T. gondii and
P. falciparum, and we believe we have achieved our goal by
developing lead compounds with dual activity.
To further develop the THQ series, 54 compounds
were synthesized to improve kinetic solubility, solubility in
physiologically-relevant media (FaSSIF, FeSSIF), and metabolic
stability (microsomes and hepatocytes), and other ADMET
properties. Compounds JAG50 and JAG21 were identified as
lead compounds, demonstrating potent inhibition on both
tachyzoites and bradyzoites life stages and were not toxic to
human cells in our in vitro model (HFF). In addition, both
compounds displayed low nanomolar efficacy against multiple
drug resistant strains of P. falciparum in vitro. JAG50 and JAG21
demonstrate promising ADMET properties, with JAG21 slightly
superior due to the compound’s longer metabolic stability in
human and mouse microsomes.
A striking result with JAG21 in our in vivo parasite studies
is the compound’s high efficacy against T. gondii tachyzoites
and bradyzoites. In our P. berghei in vivo model for malaria,
we observed that a single dose causal prophylaxis in 5 C57BL/6
albino mice at 2.5 mpk dosed on day 0, 1 h after intravenous
administration of 10,000 P. berghei sporozoites was achieved.
Causal prophylaxis was also observed after a 3-dose treatment in
5 C57BL/6 albinomice at 0.6mpk dosed on days−1, 0, and+1. A
representative figure at a higher dose (5 mg/kg) is shown, and all
experiments with the amounts mentioned above demonstrated
identical high efficacy in luminescence, parasitemia, and survival
results. This demonstrates that JAG21 functions better in this in
vivo model than the ELQ 300 series where prodrug formulation
is required to achieve solubility and efficacy, in contrast to the
efficacy of JAG21 at 2.5 mg/kg in a single oral dose model
resulting in cure without a prodrug. ELQ 300 (not the prodrug)
was not effective at doses between 1 and 20 mg/kg although the
prodrug was more effective (Doggett et al., 2012; Frueh et al.,
2017).
JAG50 and JAG21 are lead compounds, with JAG21 being
a superior compound due to its favorable predicted ADMET
properties, potency, efficacy, and lack of toxicity. JAG21
demonstrates increased solubility and potential for advanced
formulation. There also is potential for improving solubility
and reducing toxicity further because of the larger binding
pocket in the apicomplexan Cytbc1 enzyme compared with the
mammalian Cytbc1 enzyme. This was determined by modeling
occupancy of the structure, enzyme assays and empirically.
We have created and tested additional compounds that take
advantage of these properties, although none at present, have
the proven ADMET and marked in vivo efficacy we found to
be advantageous in our proof of principle studies of JAG21. At
present, however, our mature lead compound has sufficient drug
like properties to move to advanced formulations, suggesting
increased bulk will not be needed to reduce toxicity. It has
Frontiers in Cellular and Infection Microbiology | www.frontiersin.org 24 June 2020 | Volume 10 | Article 203
McPhillie et al. Potent Tetrahydroquinolone Eliminates Apicomplexan Parasites
selectivity as demonstrated by our enzymatic, binding, and
structure studies, although there are additional compounds that
show even greater selectivity. It is highly effective in an oral nano
preparation against P. berghei’s three life cycle stages, and with
early treatment appears to be capable of curing toxoplasmosis in
immunocompetent mice. This work demonstrates the promising
nature of this novel tetrahydroquinolone scaffold and mature
lead compound. JAG21 has the potential to become an orally
administered medicine or with partners, part of a medicine
combination that is curative for toxoplasmosis and is a
single dose cure for malaria. It is suitable for partnering
with other compounds to obviate problems with selection of
resistant mutants. We have demonstrated earlier that the parent
compound with this new scaffold is synergistic with atovaquone
and additive with cycloguanil (in proguanil) against P. falciparum
(McPhillie et al., 2016). Herein, we also found synergy between
JAG21 and atovaquone against T. gondii tachyzoites in vitro.
This compound is a mature lead compound to treat both T.
gondii and Plasmodium species infections. If utility and safety
retained, and no toxicity appears in next stage studies, this
compound may become suitable for treatment of T. gondii and
P. falciparum infections.
CONCLUSION
JAG21 has real promise as a mature lead compound to treat both
T. gondii and Plasmodium species infections, demonstrated in
vitro and in vivo. It has high efficacy against T. gondii tachyzoites
and bradyzoites, and established encysted organisms. Treatment
with a single low oral dose is effective for causal prophylaxis and
radical cure of P. berghei infections. JAG 21 has complete efficacy
against three life cycle stages of P. berghei. In terms of companion
inhibitors, JAG21, a Qi inhibitor, synergizes against tachyzoites
with atovaquone (a Qo inhibitor) in vitro. It appears able to
contribute modestly to protection of immune compromisedmice
in conjunction with tafenoquine against an initially replicating,
thenG1 arrested,T. gondii parasite that shares key transcriptomic
components with P. cynomolgi hypnozoites. Our mature lead
compound has sufficient selectivity and drug-like properties
to support ongoing efforts to further develop this compound
through preparation of advanced formulations and testing in
additional studies of pharmacokinetics, efficacy, and safety.
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